<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Community views on mass drug administration for filariasis: a qualitative evidence synthesis - Taylor, M - 2022 | Cochrane Library</title> <meta content="Community views on mass drug administration for filariasis: a qualitative evidence synthesis - Taylor, M - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013638.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Community views on mass drug administration for filariasis: a qualitative evidence synthesis - Taylor, M - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013638.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013638.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Community views on mass drug administration for filariasis: a qualitative evidence synthesis" name="citation_title"/> <meta content="Melissa Taylor" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="melissa.taylor@lstmed.ac.uk" name="citation_author_email"/> <meta content="Rebecca Thomas" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Sandy Oliver" name="citation_author"/> <meta content="Paul Garner" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD013638.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/02/17" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013638.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013638.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013638.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Communication; *Filariasis; Health Personnel; *Mass Drug Administration; Qualitative Research" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013638.pub2&amp;doi=10.1002/14651858.CD013638.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="UiM8QuvV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013638\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013638\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013638\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013638\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","pt","ms","fa","fr"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD013638.pub2",title:"Community views on mass drug administration for filariasis: a qualitative evidence synthesis",firstPublishedDate:"Feb 17, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UiM8QuvV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013638.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013638.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013638.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013638.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013638.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013638.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013638.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013638.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013638.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013638.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4213 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013638.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/full#CD013638-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/full#CD013638-sec-0064"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/full#CD013638-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/full#CD013638-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/full#CD013638-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/full#CD013638-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/full#CD013638-sec-0036"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/full#CD013638-sec-0060"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/appendices#CD013638-sec-0069"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Qualitative</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Community views on mass drug administration for filariasis: a qualitative evidence synthesis </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/information#CD013638-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Melissa Taylor</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/information#CD013638-cr-0005">Rebecca Thomas</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/information#CD013638-cr-0006">Sandy Oliver</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013638.pub2/information#CD013638-cr-0007">Paul Garner</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/information/en#CD013638-sec-0076">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 17 February 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013638.pub2">https://doi.org/10.1002/14651858.CD013638.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013638-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013638-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013638-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013638-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013638-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD013638-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013638-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013638-abs-0001" lang="en"> <section id="CD013638-sec-0001"> <h3 class="title" id="CD013638-sec-0001">Background</h3> <p>The World Health Organization (WHO) recommends mass drug administration (MDA), giving a drug at regular intervals to a whole population, as part of the strategy for several disease control programmes in low‐ and middle‐income countries. MDA is currently WHO policy for areas endemic with lymphatic filariasis, which is a parasitic disease that can result in swollen limbs and disability. The success depends on communities adhering to the drugs given, and this will be influenced by the perception of the drug, the programme, and those delivering it.  </p> </section> <section id="CD013638-sec-0002"> <h3 class="title" id="CD013638-sec-0002">Objectives</h3> <p>To synthesize qualitative research evidence about community experience with, and understanding and perception of, MDA programmes for lymphatic filariasis. </p> <p>To explore whether programme design and delivery influence the community experience identified in the analysis. </p> </section> <section id="CD013638-sec-0003"> <h3 class="title" id="CD013638-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, and seven other databases up to 8 April 2021, together with reference checking, citation searching, and contact with study authors to identify additional studies. </p> </section> <section id="CD013638-sec-0004"> <h3 class="title" id="CD013638-sec-0004">Selection criteria</h3> <p>This review synthesized qualitative research and mixed‐methods studies when it was possible to extract qualitative data. Eligible studies explored community experiences, perceptions, or attitudes towards MDA programmes for lymphatic filariasis in any country, conducted between 2000 and 2019.  </p> </section> <section id="CD013638-sec-0005"> <h3 class="title" id="CD013638-sec-0005">Data collection and analysis</h3> <p>We extracted data on study design including: authors, aims, participants, methods, and qualitative data collection methods. We also described programme delivery factors including: country, urban or rural setting, endemicity, drug regimen, rounds of MDA received at the time of the study, who delivered the drugs, how the drugs were delivered, use of health education, and sensitization and adherence monitoring. </p> <p>We conducted a thematic analysis and developed codes inductively using ATLAS.ti software. We examined codes for underlying ideas, connections, and interpretations and, from this, generated analytical themes. We assessed the confidence in the findings using the GRADE‐CERQual approach, and produced a conceptual model to display our findings.  </p> </section> <section id="CD013638-sec-0006"> <h3 class="title" id="CD013638-sec-0006">Main results</h3> <p>From 902 results identified in the search, 29 studies met our inclusion criteria. The studies covered a broad range of countries in Africa, South‐East Asia, and South America, and explored the views and experiences of community members and community drug distributors in low‐income countries endemic for lymphatic filariasis. Four themes emerged. </p> <p><b>People weigh up benefits and harms before participating</b>. People understand the potential benefits in terms of relief of suffering, stigma, and avoiding costs (high confidence); however, these theoretical benefits do not always mesh with their experiences (high confidence). In particular, adverse effects are frightening and unwelcome (high confidence); and these effects are amplified through rumour and social media (moderate confidence). </p> <p><b>Many people are suspicious of MDA programmes.</b> When people lack a scientific explanation for the programme and their experiences of it, they often develop social explanations instead. These are largely shaped on the historical backdrop and level of trust people have in relevant authority figures (high confidence), although some have unwavering faith in their government and, by extension, the programme (moderate confidence). </p> <p><b>Programmes expect compliance, and this can become coercive and blaming.</b> Health workers and community members stigmatize non‐compliance, which can become coercive (moderate confidence), so communities may appear to comply publicly, but privately reject treatment (moderate confidence). </p> <p><b>Community distributors are often not respected or valued.</b> They have little authority (moderate confidence), and the behaviour of some distributors damages the MDA programme's reputation (high confidence). Communities want information about programmes to help make decisions about participation, but drug distributors are not sufficiently informed, or skilled in this communication (high confidence). </p> <p>We intended to assess whether programme designs influenced communities' perceptions of the programme and decision to adhere but were unable to do so as few studies adequately reported the design and implementation of the local programme. </p> <p>We have moderate to high confidence in the evidence contributing to the review themes and subthemes. </p> </section> <section id="CD013638-sec-0007"> <h3 class="title" id="CD013638-sec-0007">Authors' conclusions</h3> <p>Adherence with MDA for filariasis is influenced by individual direct experience of benefit and harm; social influences in the community; political influences and their relationship to government; and historical influences. Fear of adverse effects was frequently described and this appears to be particularly important for communities. When views were negative, we were surprised by the strength of feeling expressed. Enthusiasm for these schemes as a strategy in global policy needs debate in the light of these findings. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013638-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013638-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013638-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013638-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013638-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013638-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD013638-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013638-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013638-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013638-abs-0002" lang="en"> <h3>Community views on mass drug administration for filariasis: a qualitative evidence synthesis </h3> <p><b>What was studied in this synthesis?</b> </p> <p>Mass drug administration (MDA) involves the regular delivery of treatment medicines to whole populations, regardless of whether an individual has the disease or not, and aims to prevent onward transmission (passing from one person to another). It is currently recommended for some disease control programmes in low‐ and middle‐income countries, including the parasitic disease lymphatic filariasis, which can result in swollen limbs and disability. For governments and their health service this is a large logistical task requiring money and staff, and success depends on communities taking the medicines given.  </p> <p>In this review, we looked for studies that explored how people view and experience these programmes. We collected all relevant studies and included 29 in this synthesis. </p> <p><b>What was the aim of this synthesis?</b> </p> <p>In this synthesis of qualitative research, we aimed to explore people's views on MDA programmes for treating lymphatic filariasis in low‐ and middle‐income countries.  </p> <p><b>Key messages </b> </p> <p>People must weigh up a number of factors before deciding to take the medicines. Not everyone benefits from MDA and some may experience harms. The decision to adhere therefore, depends on a complex balance between their trust in the government distributing the medicines; their prior understanding of the disease and the knowledge they receive on the programme; their experience of harms; the influence of family, neighbours, and health staff; and their experience and perception of the people distributing the medicines.  </p> <p><b>What were the main findings?</b> </p> <p>We included 29 studies in our analysis. The studies covered a broad range of countries in Africa, South‐East Asia, and South America, although most were conducted in India. These studies primarily explored the views and experiences of community members and those distributing the medicines in low‐income countries where lymphatic filariasis is considered a problem. From the data, four themes emerged. </p> <p>People weigh up benefits and harms before participating. People understand they can reduce the suffering, stigma and costs of developing the disease (high confidence); however, these benefits do not always mesh with their experiences (high confidence). In particular, side effects are frightening and unwelcome (high confidence); and these effects are amplified through rumour and social media (moderate confidence). </p> <p>Many people are suspicious of MDA programmes. When people lack a detailed explanation for the programme and their experiences of it, they often develop explanations based on the historical backdrop and level of trust people have in relevant authority figures (high confidence), although some have unwavering faith in their government and by extension the programme (moderate confidence). </p> <p>Programmes expect compliance, and this can become coercive and blaming. Health workers and community members stigmatize non‐compliance, which can become coercive (moderate confidence), so communities may appear to comply publicly, but privately reject treatment (moderate confidence). </p> <p>Community distributors are often not respected or valued. They have little authority (moderate confidence), and the behaviour of some damages the MDA programme's reputation (high confidence). Communities want information about programmes to help make decisions about participation, but drug distributors are not sufficiently informed, or skilled in this communication (high confidence). </p> <p>We were unable to assess the impact of programme design on communities' perception of the programme and decision to adhere as these aspects were too similar across all studies.  </p> <p><b>How up to date was this synthesis?</b> </p> <p>We searched for studies published before 8 April 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013638-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013638-sec-0064"></div> <section id="CD013638-sec-0065"> <h3 class="title" id="CD013638-sec-0065">Implications for practice</h3> <p>Despite the reported benefits and success of mass drug administration (MDA) programmes in the global literature, this review describes some fundamental community concerns and suspicions, including beliefs of harmful ulterior motives and fears surrounding adverse effects of treatment. These concerns likely provide substantive barriers to the effective delivery of MDA.  </p> <p>We are not convinced that these problems can be fixed by simply training health workers better (for example). The current problems with adherence must give rise to questions over the assumptions in the current MDA model. Is MDA acceptable to recipient communities? While we were unable to identify any particular components of programme design and delivery that influenced the views of community members, our findings do suggest some important considerations for future practice. </p> <p> <ul id="CD013638-list-0010"> <li> <p>Policymakers and providers need to ensure distribution targets do not create an atmosphere in which non‐adherence is stigmatized, as this may further erode the trust and co‐operation on which the programme depends. </p> </li> <li> <p>Improved education and sensitization is desired by recipient communities and may help to address the fears and misinformation, but needs to be sensitive and responsive to the local experiences and context. </p> </li> <li> <p>Communities need to be informed about adverse effects in advance, what they represent, and how they should manage them. In addition, after‐care may be provided, whereby a doctor is present at the distribution and for some time afterwards to manage any serious adverse effects. </p> </li> <li> <p>Community drug distributors require improved training and status in the community so that their instruction is both trusted and valued. </p> </li> <li> <p>Pre‐existing experiences and narratives shape the interpretation of both benefits and harms. Greater involvement of the community in planning and implementation may help here </p> </li> </ul> </p> <p>It is likely these findings are relevant to other MDA programmes in low‐ to middle‐income countries, including MDA for soil‐transmitted helminths, schistosomiasis, onchocerciasis, or malaria.  </p> </section> <section id="CD013638-sec-0066"> <h3 class="title" id="CD013638-sec-0066">Implications for research</h3> <p>Most of our findings are well‐supported in the literature, both for MDA programmes for filariasis and also for other parasitic infections such as schistosomiasis and soil‐transmitted helminths. However, Theme 3 (Programmes expect compliance: this can result in coercion and blame) of our review is currently graded as moderate‐confidence evidence for all subthemes. While it fits in with some other findings, we would encourage more careful research across a range of settings to explore if this is a common finding and increase our confidence that this is true and occurs more generally.  </p> <p>In addition, we found that study reporting was often poor and recommend the following areas for improvement.  </p> <p> <ul id="CD013638-list-0011"> <li> <p>Most studies were graded as low reliability due to the lack of reporting of data collection and analysis. In particular, few studies included a reflexivity statement. </p> </li> <li> <p>Future research should describe aspects of the local programme delivery in the study setting, as this will allow for analysis of how these factors impact community views and decisions to adhere. </p> </li> </ul> </p> <p>Further operational research at a local level may help highlight and alleviate some barriers identified here, although the very substantive range of problems suggest the impact of such modifications may be limited. </p> <p>Further research with other MDA programmes and vertical disease programmes in general is urgently required and seems likely to be higher on the agenda as decolonization is discussed more widely in global health. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013638-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013638-sec-0008"></div> <div class="table" id="CD013638-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> <p><b>Theme</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Subtheme</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Studies with information giving rise to the evidence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CERQual rating</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Explanation of CERQual rating </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1: people weigh up benefits and harms before adhering</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1: the perceived benefits relate to the relief of suffering, stigma, and costs of disease </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a><sup>b</sup>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a><sup>d</sup>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a><sup>c,f,g,h,i</sup>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a><sup>k</sup>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coherence, adequacy, and relevance: no or very minor concerns</p> <p>Methodological limitations: minor concerns </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2: adverse effects are a frightening and unwelcome experience</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a><sup>a</sup>;<a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a><sup>c,f,g,h,i</sup>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a><sup>k</sup>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coherence, adequacy, and relevance: no or very minor concerns</p> <p>Methodological limitations: minor concerns</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3: news of adverse effects spreads rapidly and makes people fearful</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a><sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relevance: no or very minor concerns</p> <p>Coherence, adequacy, and methodological limitations: minor concerns</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4: deciding to adhere draws on personal and shared experiences and is complex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a><sup>c,f,g,h,i</sup>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a><sup>k</sup>; <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a><sup>i</sup>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coherence, adequacy, and relevance: no or very minor concerns</p> <p>Methodological limitations: minor concerns</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2: many people are suspicious of MDA programmes</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1: many people do not trust the programme and believe there is an ulterior motive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a><sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High confidence<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coherence, relevance, and adequacy: no or very minor concerns</p> <p>Methodological limitations: minor concerns </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2: some have an unquestioning attitude to government and a lack of agency, leading to unwavering faith in the programme </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methodological limitations: no or minor concerns </p> <p>Coherence, relevance and adequacy: moderate concerns</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3: programmes expect compliance: this can result in coercive and blaming delivery</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1: health workers may become authoritarian to ensure compliance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coherence: no or very minor concerns</p> <p>Adequacy, relevance, and methodological limitations: minor concerns</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2: community members may become coercive, and stigmatize non‐compliance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coherence and methodological limitations: no or very minor concerns</p> <p>Relevancy and adequacy: minor concerns </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3: outward compliance, private rejection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a><sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relevance: no or very minor concerns</p> <p>Coherence, adequacy, and methodological limitations: minor concerns </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4: distributor's status in the community is often low, and they are not well‐equipped to answer the communities questions </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 4.1: CDDs have limited authority</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a><sup>c,f,g,h,i</sup>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a><sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequacy and relevance: no or very minor concerns</p> <p>Coherence and methodological limitations: minor concerns</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2: people prefer CDDs that are well known to the community and have good behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a><sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coherence, adequacy, and relevance: no or very minor concerns</p> <p>Methodological limitations: minor concerns </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3: people seek clarification and rationale, but do not always receive it</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> High confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coherence, adequacy, and relevance: no or very minor concerns</p> <p>Methodological limitations: minor concerns</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CDD: community drug distributor.<br/><sup>a</sup>Ghana; <sup>b</sup>Philippines; <sup>c</sup>India; <sup>d</sup>Dominican Republic; <sup>e</sup>Tanzania; <sup>f</sup>Indonesia; <sup>g</sup>Papua New Guinea; <sup>h</sup>Fiji; <sup>i</sup>Haiti; <sup>j</sup>Kenya; <sup>k</sup>Zambia. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013638-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013638-sec-0009"></div> <section id="CD013638-sec-0010"> <h3 class="title" id="CD013638-sec-0010">Description of the topic</h3> <p>Lymphatic filariasis (LF) causes ill health and disability in millions of people, particularly among the poor (<a href="./references#CD013638-bbs2-0102" title="MolyneuxD . Neglected tropical diseases. Community Eye Health Journal2013;26(82):21-4.">Molyneux 2013</a>). It is one of the neglected tropical diseases (NTDs), which are communicable diseases endemic to tropical and subtropical countries, and the World Health Organization (WHO) recommends mass drug administration (MDA) to eliminate the disease. Indeed, the WHO recommend MDA for all five of the most common NTDs: LF, onchocerciasis, soil‐transmitted helminths, schistosomiasis, and trachoma (<a href="./references#CD013638-bbs2-0118" title="WebsterJP , MolyneuxDH , HotezPJ , FenwickA . The contribution of mass drug administration to global health: past, present and future. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences2014;369(1645):20130434.">Webster 2014</a>). </p> <p>Symptomatic chronic filarial infection causes limb and genital swelling, peeling of the skin, and fevers. Without treatment, the infection persists, and without early treatment, some effects are irreversible and can cause substantive morbidity and disability in adults who are infected (<a href="./references#CD013638-bbs2-0123" title="World Health Organization. Lymphatic filariasis: Global Programme to Eliminate Lymphatic Filariasis. www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis (accessed 15 December 2019).">WHO 2019</a>). </p> <p>LF occurs in clearly geographically defined areas of the tropics and is transmitted by a variety of mosquito species, mainly species of the genus <i>Anopheles</i> or <i>Culex</i>. Repeated exposure to the bite of infected mosquitoes is required to infect people; hence vector control is an important preventive measure (<a href="./references#CD013638-bbs2-0123" title="World Health Organization. Lymphatic filariasis: Global Programme to Eliminate Lymphatic Filariasis. www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis (accessed 15 December 2019).">WHO 2019</a>). A variety of highly effective drugs are available for treatment, including diethylcarbamazine (DEC), ivermectin, and albendazole (<a href="./references#CD013638-bbs2-0123" title="World Health Organization. Lymphatic filariasis: Global Programme to Eliminate Lymphatic Filariasis. www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis (accessed 15 December 2019).">WHO 2019</a>),  </p> <p>Apart from vector control, the main tool for eliminating transmission of the disease is treatment of the disease through suppression of microfilaraemia with drugs known to be effective as tablets, or sometimes with medicated salt (<a href="./references#CD013638-bbs2-0072" title="AdinarayananS , CritchleyJA , DasPK , GelbandH . Diethylcarbamazine (DEC)‐medicated salt for community‐based control of lymphatic filariasis. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD003758. [DOI: 10.1002/14651858.CD003758.pub2]">Adinarayanan 2007</a>). This suppression is needed for the whole population over long periods of time, and MDA to treat the whole population every year is the approach used most often (<a href="./references#CD013638-bbs2-0123" title="World Health Organization. Lymphatic filariasis: Global Programme to Eliminate Lymphatic Filariasis. www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis (accessed 15 December 2019).">WHO 2019</a>).  </p> <p>The 2000 WHO Global Programme to Eliminate Lymphatic Filariasis (GPELF) has been important and continues; in addition, more integrative attempts are being made to treat multiple diseases through MDA programmes in which several drugs are given together to combat LF, soil‐transmitted helminths, schistosomiasis, onchocerciasis, and trachoma (<a href="./references#CD013638-bbs2-0118" title="WebsterJP , MolyneuxDH , HotezPJ , FenwickA . The contribution of mass drug administration to global health: past, present and future. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences2014;369(1645):20130434.">Webster 2014</a>). Although it is clear that MDA if given as recommended helps to reduce transmission, some authors report difficulties in delivery at a local level (<a href="./references#CD013638-bbs2-0106" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45.">Parker 2013b</a>). Parker and colleagues pointed out that the large financial inputs (valued at USD 2 billion and USD 3 billion annually; <a href="./references#CD013638-bbs2-0118" title="WebsterJP , MolyneuxDH , HotezPJ , FenwickA . The contribution of mass drug administration to global health: past, present and future. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences2014;369(1645):20130434.">Webster 2014</a>) may inadvertently create pressure to highlight programme success without acknowledging these difficulties (<a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>). Indeed, by 2015, governments and donors had distributed over 6.7 billion tablets for treatment of LF alone (<a href="./references#CD013638-bbs2-0114" title="SpechtS , SumaTK , PedriqueB , HoeraufA . Elimination of lymphatic filariasis in South East Asia. BMJ2019;364:k5198.">Specht 2019</a>). However, to deliver medication on such a scale is a huge logistical task involving co‐ordination between multiple sectors (<a href="./references#CD013638-bbs2-0087" title="GyapongJO , OwusuIO , Da-Costa VroomFB , MensahEO , GyapongM . Elimination of lymphatic filariasis: current perspectives on mass drug administration. Research and Reports in Tropical Medicine2018;9:25-33.">Gyapong 2018</a>). At the local level, village volunteers must identify, record, and inform the eligible population; this is followed by fixed day distribution (<a href="./references#CD013638-bbs2-0073" title="AllenT , ParkerM . The 'other diseases' of the millennium development goals: rhetoric and reality of free drug distribution to cure the poor's parasites. Third World Quarterly2011;32(1):91-117.">Allen 2011</a>). Volunteers visit villages over a large geographical distance after completing a normal day's work. The work is unpaid and may have to be repeated if people are not at home for the first planned visit (<a href="./references#CD013638-bbs2-0073" title="AllenT , ParkerM . The 'other diseases' of the millennium development goals: rhetoric and reality of free drug distribution to cure the poor's parasites. Third World Quarterly2011;32(1):91-117.">Allen 2011</a>). This can lead to shortcuts, with some distributors opting to give the tablets to one family member without ensuring that the entire family ingest them (<a href="./references#CD013638-bbs2-0076" title="BabuBV , BabuGR . Coverage of, and compliance with, mass drug administration under the programme to eliminate lymphatic filariasis in India: a systematic review. Transactions of the Royal Society of Tropical Medicine and Hygiene2014;108(9):538-49.">Babu 2014</a>).  </p> <p>Finally, regular delivery of medicines assumes that people adhere to treatment. Although providers have the intention of doing public good, this does not always mean that communities are willing to take the drugs (<a href="./references#CD013638-bbs2-0073" title="AllenT , ParkerM . The 'other diseases' of the millennium development goals: rhetoric and reality of free drug distribution to cure the poor's parasites. Third World Quarterly2011;32(1):91-117.">Allen 2011</a>). Cross‐sectional surveys conducted in India, Fiji, and Ghana estimate adherence levels between 67% and 96% (<a href="./references#CD013638-bbs2-0077" title="BhuePK , MajhiP , PandaM . Coverage and compliance of mass drug administration for elimination of lymphatic filariasis in a district of western Odisha, India. Journal of Evidence Based Medicine and Healthcare 2021;8(4):2058-63.">Bhue 2021</a>; <a href="./references#CD013638-bbs2-0085" title="DickoI , CoulibalyYI , SangaréM , SarfoB , NorteyPA . Non-compliance to mass drug administration associated with the low perception of the community members about their susceptibility to lymphatic filariasis in Ankobra, Ghana. Infectious Disorders - Drug Targets 2020;20(2):167-74. [DOI: 10.2174/1871526519666190206210808]">Dicko 2020</a>; <a href="./references#CD013638-bbs2-0093" title="KulkarniP , ThomasJJ , DowerahJ , NarayanaMR , RavikumarMK . Mass drug administration programme against lymphatic filariasis – an evaluation of coverage and compliance in a northern Karnataka district, India. Clinical Epidemiology and Global Health2019;8(1):87-90. [DOI: doi.org/10.1016/j.cegh.2019.04.013]">Kulkarni 2019</a>; <a href="./references#CD013638-bbs2-0109" title="Rinamalo M, Pezzoli L, Kama M, Rafai E, Kubuabola I, SalusaluM , et al. Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: a methodological approach. PLoS One2020;15(9):e0238622. [DOI: 10.1371/journal.pone.0238622]">Rinamalo 2020</a>). While this appears to be high, all four studies were conducted in areas of sustained LF transmission despite more than 10 years of MDA. The studies used health workers to interview community members about their participation in the most recent round of MDA, and it may be that people tend to over report their adherence in these situations. One retrospective study conducted in Ghana analyzed information from district health registers and found that compliance was much lower: 83% of the population missed at least one MDA in the previous three years, while 9.2% missed all three previous MDA (<a href="./references#CD013638-bbs2-0084" title="deSouzaDK , GassK , OtchereJ , HtetYM , AsieduO , MarfoB , et al. Review of MDA registers for lymphatic filariasis: findings, and potential uses in addressing the endgame elimination challenges. PLoS Neglected Tropical Diseases 2020;14(5): e0008306. [DOI: 10.1371/journal.pntd.0008306]">de Souza 2020</a>). Despite the success of GPELF in eliminating LF in 17 countries to date, a further 48 remain endemic (<a href="./references#CD013638-bbs2-0124" title="World Health Organization. Global Programme to Eliminate Lymphatic Filariasis: progress report, 2020. www.who.int/publications/i/item/who-wer9641-497-508 (accessed 19 December 2021).">WHO 2020</a>). Therefore, it is important to understand the contexts in which MDA is not working to tailor implementation recommendations.  </p> <p>For example, It seems possible that the occurrence of adverse effects (AEs) may influence people's willingness to comply with MDA programmes (<a href="./references#CD013638-bbs2-0082" title="CabralS , BonfimC , OliveiraR , OliveiraP , GuimarãesT , BrandãoE , et al. Knowledge, attitudes and perceptions regarding lymphatic filariasis: study on systematic noncompliance with mass drug administration. Revista do Instituto de Medicina Tropical de Sao Paulo2017;59:e23.">Cabral 2017</a>). We know that among people with active infection, AEs are common with treatment. The death of filarial parasites can cause a local inflammatory response; therefore, when filarial load is high or worms are killed too rapidly, drug administration often leads to AEs (<a href="./references#CD013638-bbs2-0090" title="KafleK . Investigation of serious adverse events following mass drug administration (MDA) 2011 for lymphatic filariasis elimination in Nepal. Technical report August 2011. www.researchgate.net/publication/279195304_Investigation_of_serious_adverse_events_following_Mass_Drug_Administration_MDA_2011_for_lymphatic_filariasis_elimination_in_Nepal (accessed 15 December 2019).">Kafle 2011</a>). Mild reactions include fever and nausea, and serious AEs are those that lead to life‐threatening or incapacitating conditions and hospitalizations (<a href="./references#CD013638-bbs2-0098" title="LimaAW , MedeirosZ , SantosZC , CostaGM , BragaC . Adverse reactions following mass drug administration with diethylcarbamazine in lymphatic filariasis endemic areas in the Northeast of Brazil. Revista de Sociedade Brasileira de Medicina Tropical2012;45(6):745-50.">Lima 2012</a>). With MDA, it is unclear whether these AEs are common as reporting and reporting accuracy are variable (<a href="./references#CD013638-bbs2-0098" title="LimaAW , MedeirosZ , SantosZC , CostaGM , BragaC . Adverse reactions following mass drug administration with diethylcarbamazine in lymphatic filariasis endemic areas in the Northeast of Brazil. Revista de Sociedade Brasileira de Medicina Tropical2012;45(6):745-50.">Lima 2012</a>; <a href="./references#CD013638-bbs2-0117" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Suppl 1):S33-8.">Wamae 2011</a>; <a href="./references#CD013638-bbs2-0119" title="WeerasooriyaMV , KimuraE , DayaratnaDA , WeerasooriyaTR , SamarawickremaWA . Efficacy of a single dose treatment of Wuchereria bancrofti microfilaria carriers with diethylcarbamazine in Matara, Sri Lanka. Ceylon Medical Journal1998;43(3):151-5.">Weerasooriya 1998</a>; <a href="./references#CD013638-bbs2-0121" title="World Health Organization. Report on active surveillance for adverse events following the use of drug co-administrations in the Global Programme to Eliminate Lymphatic Filariasis. Weekly Epidemiological Report2003;78(36):313-20.">WHO 2003</a>). Although the uninfected population does not experience AEs, those who are infected may, and this could interfere with subsequent adherence to drug treatment (<a href="./references#CD013638-bbs2-0101" title="MishraS . Over 1,300 fall ill at filariasis vaccination drive in Jharkhand; villagers attack health staff. www.hindustantimes.com/ranchi/over-1-300-fall-ill-at-filariasis-vaccination-drive-in-jharkhand-villagers-attack-health-staff/story-CCWxD4ztoh62gBFUxUVDWK.html (accessed 10 December 2019).">Mishra 2019</a>). </p> </section> <section id="CD013638-sec-0011"> <h3 class="title" id="CD013638-sec-0011">How the intervention might work</h3> <p>In terms of drug effects, LF is treated with either albendazole alone or in combination with ivermectin or DEC. These treatments reduce microfilarial levels in the infected individual, and in some cases completely clear infection (<a href="./references#CD013638-bbs2-0089" title="IsmailMM , JayakodyRL , WeilGJ , FernandoD , De SilvaMS , De SilvaGA , et al. Long-term efficacy of single-dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Transactions of the Royal Society of Tropical Medicine and Hygiene2001;95(3):332-5.">Ismail 2001</a>). When given to whole populations repeatedly over several years, MDA can reduce filaria levels to the point where transmission can no longer be sustained (<a href="./references#CD013638-bbs2-0087" title="GyapongJO , OwusuIO , Da-Costa VroomFB , MensahEO , GyapongM . Elimination of lymphatic filariasis: current perspectives on mass drug administration. Research and Reports in Tropical Medicine2018;9:25-33.">Gyapong 2018</a>). For this reason, the WHO currently recommends that at least 65% of the population should receive MDA for at least five years to achieve elimination (<a href="./references#CD013638-bbs2-0123" title="World Health Organization. Lymphatic filariasis: Global Programme to Eliminate Lymphatic Filariasis. www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis (accessed 15 December 2019).">WHO 2019</a>).  </p> <p>In terms of delivery of the drug, MDA itself simply means giving the drug to whole populations, but this is a general term for a process that can take a variously organized and managed approach, with the various approaches themselves likely to influence the effectiveness of delivery. For example, MDA can be delivered by government health staff, by community health workers, or through schools; it can be provided through mobile camps or by door‐to‐door visiting; the procedure may include careful household mapping and adherence recording, or very little attempt may be made to monitor actual ingestion. </p> <p>Delivery may take place alongside health education or sensitization initiatives such as media campaigns or public activities, whereby people are given information on the purpose of MDA along with possible opportunities to raise concerns or queries. In addition, the whole process of planning MDA can vary from imposed programmes to full 'collaborative' projects between external agencies and the community (<a href="#CD013638-tbl-0002">Table 1</a>). These programmes can be organized into top‐down, bottom‐up, and collaborative approaches, whereby the latter two have equal or majority contribution and governance from the communities intended to benefit (<a href="./references#CD013638-bbs2-0120" title="WhiteheadTI . Community based interventions, definitions and types. Cultural Ecology of Health and Change (CEHC) Working Papers Series2002;2:3-4.">Whitehead 2002</a>). Community involvement in planning and implementing interventions is thought to generate respect, trust, and sustainable support for the programme (<a href="./references#CD013638-bbs2-0097" title="LieseB , RosenbergM , SchratzA . Programmes, partnerships, and governance for elimination and control of neglected tropical diseases. Lancet2010;375(9708):67-76.">Liese 2010</a>), thereby facilitating community participation and engagement (<a href="./references#CD013638-bbs2-0075" title="AnnamalaiTR , DevkarG , MahalingamA , BenjaminS , RajanSC , DeepA . What is the evidence on top-down and bottom-up approaches in improving access to water, sanitation and electricity services in low-income or informal settlements? November 2016. eppi.ioe.ac.uk/CMS/Portals/0/PDF%20reviews%20and%20summaries/SANITATION%202016%20Annamalai.pdf (accessed 2 April 2020).">Annamalai 2016</a>). In contrast, some point out that top‐down approaches may be met with limited participation and missed opportunities to respond to problems arising at the local level (<a href="./references#CD013638-bbs2-0112" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861.">Silumbwe 2019</a>; <a href="./references#CD013638-bbs2-0115" title="SturmbergJP , NjorogeA . People‐centred health systems, a bottom‐up approach: where theory meets empery. Journal of Evaluation in Clinical Practice2017;23(2):467-73.">Sturmberg 2017</a>), but these approaches may be simpler and more practical on a large scale. One analysis of top‐down and bottom‐up approaches to water, electricity, and sanitation initiatives suggested that in areas with weak economies, governance, and existing infrastructure, bottom‐up approaches may be less effective and may require continued support from external actors (<a href="./references#CD013638-bbs2-0075" title="AnnamalaiTR , DevkarG , MahalingamA , BenjaminS , RajanSC , DeepA . What is the evidence on top-down and bottom-up approaches in improving access to water, sanitation and electricity services in low-income or informal settlements? November 2016. eppi.ioe.ac.uk/CMS/Portals/0/PDF%20reviews%20and%20summaries/SANITATION%202016%20Annamalai.pdf (accessed 2 April 2020).">Annamalai 2016</a>). </p> <div class="table" id="CD013638-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Types of delivery in mass drug administration (MDA) programmes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Form of delivery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Approach</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Programs in which individuals or groups/organizations indigenous to the community to be served by a program (target community) initiate, without any external (to that community) support". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bottom‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Programs in which individuals or community groups/organizations groups/ organizations indigenous to the community initiate, and recruit external, technical (expertise) support". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bottom‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Programs in which individuals or community‐based community based organizations (CBOs) pursue external fiscal support or funding". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bottom‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Programs in which individuals or CBOs indigenous to the target community initiate and recruit external technical and fiscal support". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bottom‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Programs which are initiated by external change agencies (public or private organization, university, a corporation, a foundation or some other philanthropic group, and so on) within a target community, but [are done] does it without any input from individual residents or organizations of that community, except as program recipients". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Top‐down</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type VI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Programs which are planned and initiated by external change agencies, and community members are eventually invited to participate on community advisory committees, or as lower‐level lower level project staff such as 'community "community outreach workers', workers", or as volunteers". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Top‐down</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type VII</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Programs which are planned and implemented as an equitable partnership by CBOs and an external change agent or technical organization". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Collaborative</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Amended from <a href="./references#CD013638-bbs2-0120" title="WhiteheadTI . Community based interventions, definitions and types. Cultural Ecology of Health and Change (CEHC) Working Papers Series2002;2:3-4.">Whitehead 2002</a>. </p> </div> </div> </section> <section id="CD013638-sec-0012"> <h3 class="title" id="CD013638-sec-0012">How this review might inform or supplement what is already known in this area</h3> <p>The <i>Cochrane Database of Systematic Reviews</i> includes two reviews regarding specific treatment regimens of MDA for LF. The first found that albendazole, given alone or in combination with other drugs, makes little difference (<a href="./references#CD013638-bbs2-0100" title="MacfarlaneC , BudhathokiSS , JohnsonS , RichardsonM , GarnerP . Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis. Cochrane Database of Systematic Reviews2019, Issue 1. Art. No: CD003753. [DOI: 10.1002/14651858.CD003753.pub4]">Macfarlane 2019</a>); and the second found DEC salt effective but only with at least 90% coverage for over six months (<a href="./references#CD013638-bbs2-0072" title="AdinarayananS , CritchleyJA , DasPK , GelbandH . Diethylcarbamazine (DEC)‐medicated salt for community‐based control of lymphatic filariasis. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD003758. [DOI: 10.1002/14651858.CD003758.pub2]">Adinarayanan 2007</a>). These disappointing findings raise the importance of investigating how people respond to MDA programmes for LP generally rather than specific drug regimens, and this is the focus of our review.  </p> <p>Before starting this review, we sought to examine the contributions of similar reviews that explored community views and responses to LF mass treatment programmes. We identified three systematic reviews and one rapid review (<a href="#CD013638-tbl-0003">Table 2</a>). One quantitative and two mixed‐methods studies largely based their findings on quantitative study designs. These designs are useful for describing known barriers and facilitators to adherence but are limited in their ability to explore unknown phenomena, provide an in‐depth understanding, and offer explanatory theory. One final study, a rapid qualitative review commissioned by the WHO (<a href="./references#CD013638-bbs2-0074" title="AmesHM , ZuskeM , KingJD , SteinmannP , Bosch-CapblanchX . Community and drug distributor perceptions and experiences of mass drug administration for the elimination of lymphatic filariasis: a rapid review of qualitative research. Advances in Parasitology2019;103:117-49.">Ames 2019</a>), was conducted in part by researchers who produced pieces of research advocating for MDA programmes (<a href="./references#CD013638-bbs2-0091" title="KingJD , Zielinski-GutierrezE , Pa'auM , LammieP . Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Tropica2011;120(Suppl 1):S48-54.">King 2011</a>). Due to the nature of rapid reviews, limited time may have been provided to develop theories from the themes identified, and only one author was involved in the analysis.  </p> <div class="table" id="CD013638-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of review studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Author</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Aims</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Methods</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Inclusion criteria</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of studies</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0076" title="BabuBV , BabuGR . Coverage of, and compliance with, mass drug administration under the programme to eliminate lymphatic filariasis in India: a systematic review. Transactions of the Royal Society of Tropical Medicine and Hygiene2014;108(9):538-49.">Babu 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"To systematically review published studies on the coverage of and compliance with MDA under the Programme for the Elimination of Lymphatic Filariasis (PELF) in India". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quantitative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013638-list-0001"> <li> <p>Up to 2013</p> </li> <li> <p>India</p> </li> <li> <p>Quantitative studies and quantitative data that can be extracted from mixed‐methods studies </p> </li> <li> <p>"Community based studies that evaluated MDA coverage and compliance conducted by the health services. Data were excluded if governmental, non‐governmental or research organizations intervened to improve compliance. However, papers that reported such studies were considered and data on control MDAs were included". </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0111" title="SilumbweA , ZuluJM , HalwindiH , JacobsC , ZgamboJ , DambeR , et al. A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa. BMC Public Health2017;17(1):484.">Silumbwe 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"To systematically document the barriers and facilitators to implementation of MDA for LF in Sub‐Saharan Africa". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed‐methods:</p> <p>qualitative (3 studies); quantitative (4 studies); mixed methods (4 studies); programme reports (6 studies); evaluation (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013638-list-0002"> <li> <p>2000–2016</p> </li> <li> <p>Sub‐Saharan Africa</p> </li> <li> <p>Studies that assessed the following outcomes: "(i) treatment coverage/compliance, (ii) program sustainability, (iii) successful implementation referring to perceptions among implementation stakeholders (both provider and community) that a given treatment, service, practice, or innovation is agreeable, palatable, or satisfactory with their needs, and (iv) community participation, defined as the involvement of the community in programme design implementation and evaluation". </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0092" title="KrentelA , FischerPU , WeilGJ . A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2013;7(11):e2447.">Krentel 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"To attempt to identify factors and patterns that are associated with compliance with MDA that apply across countries and cultures". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed‐methods: proportion of qualitative and quantitative studies unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013638-list-0003"> <li> <p>2000–2012</p> </li> <li> <p>Global</p> </li> <li> <p>"Studies that: (i) reviewed the literature on compliance with MDA for LF; (ii) described or assessed factors associated with compliance with MDA for LF; (iii) analysed, observed, or documented compliance rates with MDA and/or provided an explanation or discussion of the rates; and (iv) were identified from reference lists of primary papers". </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0074" title="AmesHM , ZuskeM , KingJD , SteinmannP , Bosch-CapblanchX . Community and drug distributor perceptions and experiences of mass drug administration for the elimination of lymphatic filariasis: a rapid review of qualitative research. Advances in Parasitology2019;103:117-49.">Ames 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"To rapidly review the existing qualitative literature to identify perspectives from the community and drug distributors. We focused on factors influencing feasibility of planning and carrying out campaigns and acceptability of MDA within community settings". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Qualitative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013638-list-0004"> <li> <p>2002–2017</p> </li> <li> <p>Global</p> </li> <li> <p>Qualitative studies and qualitative data that can be extracted from mixed‐methods studies </p> </li> <li> <p>Studies that "discussed community and/or drug distributor perceptions of and experiences with any form of MDA for LF elimination. Community encompasses people receiving treatment as well as those around them. A drug distributor can be anyone distributing medicines". </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>LF: lymphatic filariasis; MDA: mass drug administration.</p> </div> </div> <p>Driving forces outlined in the above studies include training (<a href="./references#CD013638-bbs2-0074" title="AmesHM , ZuskeM , KingJD , SteinmannP , Bosch-CapblanchX . Community and drug distributor perceptions and experiences of mass drug administration for the elimination of lymphatic filariasis: a rapid review of qualitative research. Advances in Parasitology2019;103:117-49.">Ames 2019</a>; <a href="./references#CD013638-bbs2-0111" title="SilumbweA , ZuluJM , HalwindiH , JacobsC , ZgamboJ , DambeR , et al. A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa. BMC Public Health2017;17(1):484.">Silumbwe 2017</a>), community awareness (<a href="./references#CD013638-bbs2-0111" title="SilumbweA , ZuluJM , HalwindiH , JacobsC , ZgamboJ , DambeR , et al. A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa. BMC Public Health2017;17(1):484.">Silumbwe 2017</a>), management of AEs (<a href="./references#CD013638-bbs2-0074" title="AmesHM , ZuskeM , KingJD , SteinmannP , Bosch-CapblanchX . Community and drug distributor perceptions and experiences of mass drug administration for the elimination of lymphatic filariasis: a rapid review of qualitative research. Advances in Parasitology2019;103:117-49.">Ames 2019</a>; <a href="./references#CD013638-bbs2-0092" title="KrentelA , FischerPU , WeilGJ . A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2013;7(11):e2447.">Krentel 2013</a>; <a href="./references#CD013638-bbs2-0111" title="SilumbweA , ZuluJM , HalwindiH , JacobsC , ZgamboJ , DambeR , et al. A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa. BMC Public Health2017;17(1):484.">Silumbwe 2017</a>), trust (<a href="./references#CD013638-bbs2-0074" title="AmesHM , ZuskeM , KingJD , SteinmannP , Bosch-CapblanchX . Community and drug distributor perceptions and experiences of mass drug administration for the elimination of lymphatic filariasis: a rapid review of qualitative research. Advances in Parasitology2019;103:117-49.">Ames 2019</a>; <a href="./references#CD013638-bbs2-0092" title="KrentelA , FischerPU , WeilGJ . A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2013;7(11):e2447.">Krentel 2013</a>), community involvement in planning and conducting the MDA (<a href="./references#CD013638-bbs2-0074" title="AmesHM , ZuskeM , KingJD , SteinmannP , Bosch-CapblanchX . Community and drug distributor perceptions and experiences of mass drug administration for the elimination of lymphatic filariasis: a rapid review of qualitative research. Advances in Parasitology2019;103:117-49.">Ames 2019</a>), and whether timing was convenient (<a href="./references#CD013638-bbs2-0074" title="AmesHM , ZuskeM , KingJD , SteinmannP , Bosch-CapblanchX . Community and drug distributor perceptions and experiences of mass drug administration for the elimination of lymphatic filariasis: a rapid review of qualitative research. Advances in Parasitology2019;103:117-49.">Ames 2019</a>). Restraining forces include fear of AEs (<a href="./references#CD013638-bbs2-0076" title="BabuBV , BabuGR . Coverage of, and compliance with, mass drug administration under the programme to eliminate lymphatic filariasis in India: a systematic review. Transactions of the Royal Society of Tropical Medicine and Hygiene2014;108(9):538-49.">Babu 2014</a>; <a href="./references#CD013638-bbs2-0092" title="KrentelA , FischerPU , WeilGJ . A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2013;7(11):e2447.">Krentel 2013</a>), lack of perception of benefit (<a href="./references#CD013638-bbs2-0076" title="BabuBV , BabuGR . Coverage of, and compliance with, mass drug administration under the programme to eliminate lymphatic filariasis in India: a systematic review. Transactions of the Royal Society of Tropical Medicine and Hygiene2014;108(9):538-49.">Babu 2014</a>; <a href="./references#CD013638-bbs2-0092" title="KrentelA , FischerPU , WeilGJ . A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2013;7(11):e2447.">Krentel 2013</a>), lack of information or understanding (<a href="./references#CD013638-bbs2-0074" title="AmesHM , ZuskeM , KingJD , SteinmannP , Bosch-CapblanchX . Community and drug distributor perceptions and experiences of mass drug administration for the elimination of lymphatic filariasis: a rapid review of qualitative research. Advances in Parasitology2019;103:117-49.">Ames 2019</a>; <a href="./references#CD013638-bbs2-0076" title="BabuBV , BabuGR . Coverage of, and compliance with, mass drug administration under the programme to eliminate lymphatic filariasis in India: a systematic review. Transactions of the Royal Society of Tropical Medicine and Hygiene2014;108(9):538-49.">Babu 2014</a>; <a href="./references#CD013638-bbs2-0092" title="KrentelA , FischerPU , WeilGJ . A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2013;7(11):e2447.">Krentel 2013</a>), delays in drug delivery (<a href="./references#CD013638-bbs2-0092" title="KrentelA , FischerPU , WeilGJ . A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2013;7(11):e2447.">Krentel 2013</a>; <a href="./references#CD013638-bbs2-0111" title="SilumbweA , ZuluJM , HalwindiH , JacobsC , ZgamboJ , DambeR , et al. A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa. BMC Public Health2017;17(1):484.">Silumbwe 2017</a>), lack of motivation of distributors (<a href="./references#CD013638-bbs2-0092" title="KrentelA , FischerPU , WeilGJ . A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2013;7(11):e2447.">Krentel 2013</a>), and inadequate numbers of distributors (<a href="./references#CD013638-bbs2-0074" title="AmesHM , ZuskeM , KingJD , SteinmannP , Bosch-CapblanchX . Community and drug distributor perceptions and experiences of mass drug administration for the elimination of lymphatic filariasis: a rapid review of qualitative research. Advances in Parasitology2019;103:117-49.">Ames 2019</a>). <a href="./references#CD013638-bbs2-0111" title="SilumbweA , ZuluJM , HalwindiH , JacobsC , ZgamboJ , DambeR , et al. A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa. BMC Public Health2017;17(1):484.">Silumbwe 2017</a> noted some interesting contextual factors influencing compliance, including the belief that MDA transmits Ebola, and the thought that MDA is not a priority during other outbreaks. This may suggest that it is useful to consider findings in terms of country and context. </p> <p>The conceptual model was developed from the findings of these reviews and represents the a priori understanding of the factors that influence adherence at the community level (<a href="#CD013638-fig-0001">Figure 1</a>). <a href="#CD013638-fig-0001">Figure 1</a> aimed to help us delineate our thinking before conducting the review and to explore our own thoughts on the topic. The conceptual model was used as a guide in the initial analysis and was ultimately revised in light of the findings of this review. </p> <div class="figure" id="CD013638-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Conceptual model of the driving and restraining influences on MDA delivery and adherence. AE: adverse effect; LF: lymphatic filariasis; MDA: mass drug administration." data-id="CD013638-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013638.pub2/media/CDSR/CD013638/image_n/nCD013638-FIG-01.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Conceptual model of the driving and restraining influences on MDA delivery and adherence. AE: adverse effect; LF: lymphatic filariasis; MDA: mass drug administration. </p> </div> </div> </div> </section> <section id="CD013638-sec-0013"> <h3 class="title" id="CD013638-sec-0013">Why is it important to do this review?</h3> <p>Reviews conducted previously have helped by listing driving and restraining forces of adherence. Decisions to adhere to treatment are complicated, however, and often are related to multiple competing beliefs and values and the wider sociopolitical context. Therefore, we conducted a careful analysis using recent methods in qualitative evidence synthesis (QES) to: </p> <p> <ul id="CD013638-list-0005"> <li> <p> further examine the context in which these drugs are delivered in an effort to explain when sometimes adherence is not as high, as is desired by policy‐makers, and  </p> </li> <li> <p>delineate community views to provide feedback on programme design. </p> </li> </ul> </p> <p>This approach provides the underpinning for this review, in which we aimed to synthesize the perceptions and experiences of those receiving MDA with the goal of attaining a broader understanding of the impact of programmes and consumers' openness towards them. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013638-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013638-sec-0014"></div> <p>To synthesize qualitative research evidence about community experience with, and understanding and perception of, MDA programmes for LF. </p> <p>To explore whether programme design and delivery influence the community experience identified in the analysis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013638-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013638-sec-0015"></div> <section id="CD013638-sec-0016"> <h3 class="title" id="CD013638-sec-0016">Criteria for considering studies for this review</h3> <section id="CD013638-sec-0017"> <h4 class="title">Types of studies</h4> <section id="CD013638-sec-0018"> <h5 class="title">Inclusion criteria</h5> <p>We included all qualitative research (including ethnographies, phenomenologies, qualitative process evaluations, and case studies). We defined qualitative research as studies that collected data using qualitative methods such as ethnographic observations, in‐depth interviews, focus group discussions, and open‐ended survey questions. Appropriate analysis methods included, for example, thematic analysis, narrative analysis, framework analysis, and grounded theory (<a href="./references#CD013638-bbs2-0116" title="ThomasJ , HardenA . Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Medical Research Methodology2008;8:45.">Thomas 2008</a>). </p> <p>We included mixed‐methods studies when it was possible to extract qualitative data.</p> <p>We restricted included studies to those from 2000 to present day, as this marked the date of the introduction of the GPELF and the date that MDA activities were introduced and scaled up for filariasis (<a href="./references#CD013638-bbs2-0123" title="World Health Organization. Lymphatic filariasis: Global Programme to Eliminate Lymphatic Filariasis. www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis (accessed 15 December 2019).">WHO 2019</a>). </p> <p>We included both published and unpublished studies.</p> </section> <section id="CD013638-sec-0019"> <h5 class="title">Exclusion criteria</h5> <p>We excluded studies that included qualitative data collection methods but reported and analyzed all data quantitatively. </p> <p>We excluded studies published in any language other than English.</p> </section> </section> <section id="CD013638-sec-0020"> <h4 class="title">Topics of interest</h4> <section id="CD013638-sec-0021"> <h5 class="title">Inclusion criteria </h5> <p><b>Phenomenon of interest:</b> community experiences, perceptions, or attitudes towards MDA programmes for LF. </p> <p><b>Setting:</b> any setting that provided MDA for filariasis, as the purpose of synthesis to inform decision‐making was to yield theories that were more transferable and socially relevant over a broader range of contexts. </p> <p><b>Perspectives:</b> any community member eligible for the MDA programme and village leaders. Perceptions of lay healthcare workers (HCW; those without formal training or qualifications, including community health workers and drug distributors as defined by <a href="./references#CD013638-bbs2-0095" title="LewinS , Munabi-BabigumiraS , GlentonC , DanielsK , Bosch-CapblanchX , vanWykBE , et al. Lay health workers in primary and community health care for maternal and child health and the management of infectious diseases. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD004015. [DOI: 10.1002/14651858.CD004015.pub3]">Lewin 2010</a>) and government health workers may have been included to triangulate results if they were clearly separated from the perspectives of the general consumer population. </p> <p><b>Intervention:</b> delivery of MDA, which, for this review, was defined as administration of an anti‐filarial drug to the entire at‐risk population (irrespective of symptoms or infection) on a regular, often annual, basis. Eligible drug regimens included ivermectin, albendazole, and DEC alone or in combination. During scoping, we identified that most of the available research related to compliance in MDA programmes focused on LF specifically. Therefore, this review focused on community perceptions towards MDA programmes for LF. </p> </section> <section id="CD013638-sec-0022"> <h5 class="title">Exclusion criteria</h5> <p>The literature on MDA policies and their implementation is extensive. This review was not concerned with understanding policies by those implementing them; therefore, we did not summarize the views of those affiliated with the programme design or with programme governance. When community or lay (or both) HCW voices could not be separated from programme staff, we excluded the study.  </p> </section> </section> </section> <section id="CD013638-sec-0023"> <h3 class="title" id="CD013638-sec-0023">Search methods for identification of studies</h3> <p>We developed the search strategy in consultation with Cochrane Infectious Diseases Group and Cochrane Effective Practice and Organisation of Care (EPOC) Information Specialists. </p> <section id="CD013638-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We attempted to identify all relevant studies regardless of publication status (i.e. published, unpublished, in press, or in progress). The search was first conducted on 10 December 2019 and updated on 8 April 2021. We limited our searches from publication year 2000 onwards and to studies conducted in English. We searched the following databases using the search terms and strategy described in <a href="./appendices#CD013638-sec-0070">Appendix 1</a>: Cochrane Central Register of Controlled Trials (CENTRAL), Issue 3, 2021, published in the Cochrane Library; MEDLINE (PubMed); Embase (OVID); Latin American and Caribbean Health Sciences Literature (LILACS, BIREME); Cumulative Index to Nursing and Allied Health Literature (CINAHL, EBSCOHost); Global Health (Web of Science); CAB Direct (Web of Science); and Science Citation Index – Expanded (Web of Science), ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP). </p> </section> <section id="CD013638-sec-0025"> <h4 class="title">Searching other resources</h4> <p>The Cochrane Qualitative and Implementation Methods Group recommends supplementary searching activities due to the limited availability of qualitative research. To achieve this, we scanned reference lists and perform citation searches of included studies and existing reviews identified in the <a href="#CD013638-sec-0009">Background</a>. We contacted experts in the field to ask what they knew about published and unpublished data. </p> </section> <section id="CD013638-sec-0026"> <h4 class="title">Grey literature</h4> <p>We searched OpenGrey to identify grey literature (<a href="http://www.opengrey.eu" target="_blank">www.opengrey.eu</a>). Unpublished studies may be of lower quality and reliability than published studies. However, all grey literature results were subject to quality appraisal and, during this process, we did not identify any concerns.  </p> </section> </section> <section id="CD013638-sec-0027"> <h3 class="title" id="CD013638-sec-0027">Selection of studies</h3> <p>We imported all search results into Covidence, and removed any duplicates (<a href="./references#CD013638-bbs2-0083" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 3 February 2022. Available at covidence.org.">Covidence</a>). Two review authors (MT and RT) independently screened retrieved search results against the inclusion criteria. This two‐step process consisted of screening first titles/abstracts, then full text. Using two review authors to screen is valuable in providing opportunities to explore relevance and meaning of study findings (<a href="./references#CD013638-bbs2-0113" title="SoilemeziD , LinceviciuteS . Synthesizing qualitative research: reflections and lessons learnt by two new reviewers. International Journal of Qualitative Methods2018;17:1-14.">Soilemezi 2018</a>). Studies were only included if both authors could reach a consensus decision and a third review author (PG) resolved any disagreements. We summarized this process in a PRISMA flow diagram detailing the numbers of studies removed and kept at each step (<a href="#CD013638-fig-0002">Figure 2</a>). We noted the reasons for exclusion of full‐text studies and present this information in the <a href="./references#CD013638-sec-0083" title="">Characteristics of excluded studies</a> table. </p> <div class="figure" id="CD013638-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD013638-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013638.pub2/media/CDSR/CD013638/image_n/nCD013638-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD013638-sec-0028"> <h3 class="title" id="CD013638-sec-0028">Language translation</h3> <p>Due to time and resource demands of translation, only studies available in English were eligible for inclusion. </p> </section> <section id="CD013638-sec-0029"> <h3 class="title" id="CD013638-sec-0029">Sampling of studies</h3> <p>The search yielded only 29 eligible studies and so sampling was not deemed necessary. </p> </section> <section id="CD013638-sec-0030"> <h3 class="title" id="CD013638-sec-0030">Data extraction and management</h3> <p>One review author (MT) independently extracted data on both the study design and programme delivery using a predefined data extraction form. This included the following information. </p> <p> <ul id="CD013638-list-0006"> <li> <p>Study design: author, aim, participants, methods, and qualitative data collection methods. </p> </li> <li> <p>Study context: country, urban or rural setting, endemicity, drug regimen, rounds of MDA received at the time of the study, who delivered the drugs, how the drugs were delivered, use of health education, and sensitization and adherence monitoring. We used this information to categorize each study using the seven delivery methods outlined in <a href="./references#CD013638-bbs2-0120" title="WhiteheadTI . Community based interventions, definitions and types. Cultural Ecology of Health and Change (CEHC) Working Papers Series2002;2:3-4.">Whitehead 2002</a>. Where information was unavailable, we sought other documents related to MDA policies in the country at the time to try to input some basic characteristics of the programme, and we noted which characteristics were secondarily derived from other sources. To find this information, we screened citations of the target study, then performed a Google search for other documents that referred to these programmes. </p> </li> </ul> </p> </section> <section id="CD013638-sec-0031"> <h3 class="title" id="CD013638-sec-0031">Assessing the methodological limitations of included studies</h3> <p>We assessed the methodological limitations using a standardized set of criteria to impart some objective distance and to ensure consistency. We chose a modified version of the tool developed by the EPPI‐Centre at University College London (UK) for its clear and straightforward approach and use in a similar QES investigating consumer perceptions and experiences of a health intervention (<a href="./appendices#CD013638-sec-0071">Appendix 2</a>; <a href="./references#CD013638-bbs2-0086" title="Eshun-WilsonI , RohwerA , HendricksL , OliverS , GarnerP . Being HIV positive and staying on antiretroviral therapy in Africa: a qualitative systematic review and theoretical model. PLoS One2019;14(1):e0210408.">Eshun‐Wilson 2019</a>). This tool assessed the following criteria: rigour in sampling, rigour in data collection, rigour in analysis, grounding of data, and breadth and depth of study findings. Each criterion offered several prompts to aid the user in making a judgement. For each category, studies received a score of (1) Yes, a fairly thorough attempt was made; (2) Yes, several steps were taken; (3) Yes, a few steps were taken; or (4) not stated/could not determine. Two review authors (MT and RT) independently conducted a methodological limitations' assessment of each paper before comparing findings and reaching a consensus. </p> <p>We did not exclude studies based on our assessment of methodological limitations. However, we used this information to assess our confidence in the review findings. </p> </section> <section id="CD013638-sec-0032"> <h3 class="title" id="CD013638-sec-0032">Data management, analysis, and synthesis</h3> <p>We used thematic synthesis as described in <a href="./references#CD013638-bbs2-0116" title="ThomasJ , HardenA . Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Medical Research Methodology2008;8:45.">Thomas 2008</a> and informed by the <a href="./references#CD013638-bbs2-0080" title="BraunV , ClarkeV . Using thematic analysis in psychology. Qualitative Research in Psychology2006;3(2):77-101.">Braun 2006</a> thematic analysis. Thematic synthesis assumes that knowledge of reality is mediated by perceptions and beliefs, thus making it an appropriate choice for a study investigating perceptions, experiences, and acceptability of a health intervention. This method also assumes that findings are reproducible and transferable, which aligns with the second objective of this review – to explore implications for programme delivery. We completed the following steps. </p> <p> <ul id="CD013638-list-0007"> <li> <p>Familiarizing with the data: two review authors (MT and RT) independently read relevant background literature and the full length of studies included in the review to become familiar with, and immersed in, the data, noting any initial thoughts. </p> </li> <li> <p>Generating initial codes: two review authors (MT and RT) independently began coding. Initially, we assigned codes deductively based on the findings outlined in the conceptual model (<a href="#CD013638-fig-0001">Figure 1</a>). However, as we progressed through the studies, new findings and insights lead to the development of new codes and coding, therefore, took a more inductive approach. This included both first‐ and second‐order data, with first‐order data being the original quotations, and second‐order data comprising study authors' interpretations. We attempted to retain accounts that differed from the emerging understanding of the situation. Review authors then compared individual codes on a study‐by‐study basis to reach consensus on the appropriateness and terminology of each code. The result of this process was the development of a shared coding framework that was applied to subsequent papers, which we refined and amended as new codes emerged. </p> </li> <li> <p>Searching for themes: working together, two review authors (MT and RT) grouped codes into potential themes, gathering all data relevant to each theme. Here, review authors interpreted the meaning behind the data and thought about the relationships between codes, themes, and hierarchies of themes. The wider team (MT, RT, SO, and OG) met regularly to reflect on emerging themes as a group. </p> </li> <li> <p>Reviewing themes: review authors ensured that the pattern of data within themes was coherent, and that there was a clear distinction between themes and subthemes. This involved breaking, merging, and removing themes with too little, too much, or disparate information, including subthemes that were graded 'low' certainty evidence for the coherence component of the CERQual assessment. We reviewed included studies a second time to capture any data missed for newly emerging themes. </p> </li> <li> <p>Producing the report: one review author (MT) produced a narrative of findings for each theme, integrating vivid illustrative quotes; this was then shared the wider team for feedback. </p> </li> </ul> </p> <p>We then attempted to analyze findings specific to any geographical settings or contexts, such as settings also receiving MDA for other co‐endemic diseases, poverty levels, and programme design (such as form of delivery, drug regimen, and rounds of MDA received at the time of the study). </p> <p>Finally, we completely revised the conceptual model to reflect the new understanding. Our first conceptual framework was designed as a logic model for a programme focusing on the desired outcomes, taking into account barriers and facilitators that were either anticipated or confirmed in the literature. This was developed from earlier reviews that identified driving and restraining forces of adherence, but without sufficient in‐depth analysis to examine how these factors inter‐related. In conducting our QES, as our analysis found important links between individual behaviour and the wider community, and to policies and reputations of programmes and organizations, it was easier to visualize factors of influence being nested in an ecological model inspired by Bronfenbrenner's Ecological Systems Theory (<a href="./references#CD013638-bbs2-0081" title="BronfenbrennerU . Ecological systems theory. Annals of Child Development1989;6:187-249.">Bronfenbrenner 1989</a>). This strengthens the explanations of why individuals choose to accept or avoid MDA. As with the thematic analysis process, the development of the conceptual model was inductive and subject to revision and discussion among the wider team.  </p> </section> <section id="CD013638-sec-0033"> <h3 class="title" id="CD013638-sec-0033">Assessing our confidence in review findings</h3> <p>Two review authors (MT and RT) used the GRADE‐CERQual (Confidence in the Evidence from Reviews of Qualitative Research) approach to assess confidence in each finding (subtheme) (<a href="./references#CD013638-bbs2-0096" title="LewinS , BoothA , GlentonC , Munthe-KaasH , RashidianA , WainwrightM , et al. Applying GRADE-CERQual to qualitative evidence synthesis findings: introduction to the series. Implementation Science2018;13(Suppl 1):2.">Lewin 2018</a>). CERQual assesses confidence in the evidence based on the following four key components. </p> <p> <ul id="CD013638-list-0008"> <li> <p>Methodological limitations of included studies: the extent to which there were concerns about the design or conduct of the primary studies that contributed evidence to an individual review finding. </p> </li> <li> <p>Coherence of the review finding: how clear and cogent the fit was between data from the primary studies and a review finding that synthesized those data. By 'cogent', we meant well‐supported or compelling. </p> </li> <li> <p>Adequacy of the data contributing to a review finding: the degree of richness and the quantity of data supporting a review finding. </p> </li> <li> <p>Relevance of included studies to the review question: how the body of evidence from the primary studies supported a review finding. This information was applicable to the context (perspective or population, phenomenon of interest, setting) specified in the review question. </p> </li> </ul> </p> <p>After assessing each of the four components, we judged our overall confidence in the evidence supporting the review finding. We judged confidence as high, moderate, low, or very low. All findings started as high confidence and were then downgraded if there were important concerns regarding any of the CERQual components. </p> <p>We chose to take an explanatory approach in this review with an emphasis on developing a cohesive conceptual model and theoretically generalizable findings. We consulted with a CERQual specialist during the preparation of this review and noted that the approach while useful, was mostly applicable to descriptive findings and had not been fully explored for use with explanatory findings. Therefore, we adapted their approach to fit the methodological assumptions of our review. </p> <p>A full description of how we decided on the CERQual assessments is given in the <a href="./full#CD013638-sec-0036">Results</a> and <a href="./appendices#CD013638-sec-0072">Appendix 3</a>.  </p> </section> <section id="CD013638-sec-0034"> <h3 class="title" id="CD013638-sec-0034">Summary of qualitative findings table and evidence profile</h3> <p>We presented summaries of findings and our assessments of confidence in these findings in <a href="./full#CD013638-tbl-0001">summary of findings Table 1</a>. We presented detailed descriptions of our confidence assessment in <a href="./appendices#CD013638-sec-0072">Appendix 3</a>. </p> </section> <section id="CD013638-sec-0035"> <h3 class="title" id="CD013638-sec-0035">Review author reflexivity</h3> <p>In qualitative research, we appreciate that the background and position of researchers will shape interpretation of results, and thus team positionality at the outset, through the process of analysis and synthesis. We state these broad positionality statements at the outset here. PG was the clinician organizing the delivery of MDA for LF as part of a research project in the Maprik Area of the West Sepik in the 1980s. During this time, he lived adjacent to the research village for several weeks. These populations were heavily infected with filariasis, and the DEC made people unwell, so he has seen AEs first‐hand. As a public health professional, his values and principles include believing that health professionals take account of views of the public on clinical and public health policies. His research reflects these values. MT, RT, and SO have no personal experience regarding MDA programmes and hold differing perspectives on their value. RT is working on a project on human rights and guideline development and is sensitive to policies from a human rights perspective. SO is ambivalent about MDA programmes and views them from the standpoint of families rather than practitioners. The work will build on MT's thesis, which highlighted several consumer concerns about the programme. Before she conducted this research, MT's views on MDA were influenced by her academic tuition to date, which involved a provider‐centred rhetoric that MDA is a highly effective and appropriate solution. </p> <p>Analysis was conducted by two primary analysts (MT and RT), who additionally provided feedback on their findings and interpretations to the whole research team. This involved regular meetings with PG and occasional meetings with SO. As different researchers will approach the analysis from different perspectives, this collaborative effort should produce a richer, more nuanced understanding of a complex situation while generating opportunities to identify and contest any assumptions or beliefs held by individual review authors. To further increase reflexivity in our research design, we aimed to explore and explain any findings that appeared to contradict our understanding of the situation. Primary analysts kept memo notes during the initial stages of analysis to provide a transparent account of the interpretation process and the development of themes. </p> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013638-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013638-sec-0036"></div> <section id="CD013638-sec-0037"> <h3 class="title" id="CD013638-sec-0037">Search results </h3> <p>We included 29 studies described in 33 papers after screening 902 titles and abstracts and 75 full‐texts (<a href="#CD013638-fig-0002">Figure 2</a>). <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a> and <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a> were each described across three publications. <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a> was a PhD thesis and the remainder were published in peer‐reviewed journals between 2000 and 2020. The full list of reasons for exclusion can be found in the <a href="./references#CD013638-sec-0083" title="">Characteristics of excluded studies</a> table.  </p> </section> <section id="CD013638-sec-0038"> <h3 class="title" id="CD013638-sec-0038">Description of included studies </h3> <section id="CD013638-sec-0039"> <h4 class="title">Study methods </h4> <p>The full description of study methods can be found in the <a href="./references#CD013638-sec-0082" title="">Characteristics of included studies</a> table. </p> <p>There was a mix of both qualitative studies (13; <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a>; <a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a>; <a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>; <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>); and mixed‐methods studies (16: <a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a>; <a href="./references#CD013638-bbs2-0003" title="BabuBV , SatyanarayanaK . Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Tropical Doctor2003;33(2):79-82. ">Babu 2003</a>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a>; <a href="./references#CD013638-bbs2-0013" title="KingJD , Zielinski-GutierrezE , Pa'auM , LammieP . Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Tropica2011;120(Suppl 1):S48-54. ">King 2011</a>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a>; <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a>; <a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a>). These comprised a range of qualitative data collection methods including in‐depth or semi‐structured interviews (26: <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a>; <a href="./references#CD013638-bbs2-0003" title="BabuBV , SatyanarayanaK . Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Tropical Doctor2003;33(2):79-82. ">Babu 2003</a>; <a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>; <a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a>; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a>; <a href="./references#CD013638-bbs2-0013" title="KingJD , Zielinski-GutierrezE , Pa'auM , LammieP . Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Tropica2011;120(Suppl 1):S48-54. ">King 2011</a>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a>; <a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>; <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>); observation (2: <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>); and focus group discussions (22: <a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a>; <a href="./references#CD013638-bbs2-0003" title="BabuBV , SatyanarayanaK . Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Tropical Doctor2003;33(2):79-82. ">Babu 2003</a>; <a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>; <a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a>; <a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a>; <a href="./references#CD013638-bbs2-0013" title="KingJD , Zielinski-GutierrezE , Pa'auM , LammieP . Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Tropica2011;120(Suppl 1):S48-54. ">King 2011</a>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a>; <a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>; <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>). </p> <p>Twenty‐six studies included a mix of both community members, community or religious leaders and programme or health staff including: distributors, health workers, doctors, NGO staff, and medical officers (<a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a>; <a href="./references#CD013638-bbs2-0003" title="BabuBV , SatyanarayanaK . Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Tropical Doctor2003;33(2):79-82. ">Babu 2003</a>; <a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>; <a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a>; <a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a>; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a>; <a href="./references#CD013638-bbs2-0013" title="KingJD , Zielinski-GutierrezE , Pa'auM , LammieP . Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Tropica2011;120(Suppl 1):S48-54. ">King 2011</a>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a>; <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a>;. <a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>; <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a>). Three studies selected exclusively community members (<a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>). Of which, one study purposely sampled non‐compliers (<a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>).  </p> </section> <section id="CD013638-sec-0040"> <h4 class="title">Study context</h4> <p>The full description of study context can be found in the <a href="./references#CD013638-sec-0082" title="">Characteristics of included studies</a> table and <a href="#CD013638-tbl-0004">Table 3</a>. </p> <div class="table" id="CD013638-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Programme design and delivery for included studies </span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Author</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rounds of MDA</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Programme organization</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Community engagement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Who delivers</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>How delivered</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adherence monitoring</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs and health staff</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0003" title="BabuBV , SatyanarayanaK . Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Tropical Doctor2003;33(2):79-82. ">Babu 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Yes<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0–1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0013" title="KingJD , Zielinski-GutierrezE , Pa'auM , LammieP . Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Tropica2011;120(Suppl 1):S48-54. ">King 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs and health staff</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door and "drug distribution booths set up at major work locations and the central market". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not mentioned </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door and "sometimes public places such as markets in urban areas".</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door ‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MDA‐naïve regions (Papua New Guinea, Indonesia) to 3 sites with multiple years of MDA rounds (India, Haiti, and Fiji)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"PHC network in rural areas and various categories of health staff in urban areas"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Distribution posts including: schools, markets, health facilities, churches, and local gathering places<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Village birth attendants, community based health workers,<br/>and teachers in drug distribution" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not mention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CDD: community drug distributor; MDA: mass drug administration; PHC: primary Health Centre. </p> <p>For some studies, further information was provided by a: <a href="./references#CD013638-bbs2-0079" title="Biritwum NK, Frempong KK, Verver S, Odoom S, Alomatu B, Asiedu O,  et al. Progress towards lymphatic filariasis elimination in Ghana from 2000-2016: analysis of microfilaria prevalence data from 430 communities. PLoS Neglected Tropical Diseases2019;13(8):e0007115.">Biritwum 2019</a>; b: <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a>; c: <a href="./references#CD013638-bbs2-0103" title="National Vector Bourne Disease Control Programme. Accelerated plan for elimination of lymphatic filariasis 2018. nvbdcp.gov.in/WriteReadData/l892s/1031567531528881007.pdf (accessed 19 January 2020).">NVBDCP 2018</a>; d: <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; e: <a href="./references#CD013638-bbs2-0104" title="OscarR , LemoineJF , DirenyAN , DesirL , Beau de RocharsVE , PoirierMJ , et al. Haiti National Program for the elimination of lymphatic filariasis—a model of success in the face of adversity. PLoS Neglected Tropical Diseases2014;8(7):e2915.">Oscar 2014</a>. </p> </div> </div> <p>Studies were from 10 countries across India (10: <a href="./references#CD013638-bbs2-0003" title="BabuBV , SatyanarayanaK . Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Tropical Doctor2003;33(2):79-82. ">Babu 2003</a>; <a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; <a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a>; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a>; <a href="./references#CD013638-bbs2-0051" title="KrentelA , GyapongM , McFarlandDA , OgundahunsiO , TitaleyCR , AddissDG . Keeping communities at the centre of efforts to eliminate lymphatic filariasis: learning from the past to reach a future free of lymphatic filariasis. International Health2020;13(Suppl 1):S55-9. ">Krentel 2020</a>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a>); Indonesia (2: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>); Philippines (1: <a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a>); Papua New Guinea (2: <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>); Kenya (5: <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a>; <a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>); Ghana (4: <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a>); Tanzania (3: <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>); Zambia (1: <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>); Dominican Republic (1: <a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a>); Haiti (2: <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a>); American Samoa (1: <a href="./references#CD013638-bbs2-0013" title="KingJD , Zielinski-GutierrezE , Pa'auM , LammieP . Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Tropica2011;120(Suppl 1):S48-54. ">King 2011</a>); and Fiji (1: <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>). </p> <p>Most studies described the setting as endemic for LF; while two studies included both endemic and non‐endemic areas (<a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>) and one described endemicity as 'low' (<a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>). Most studies were conducted in mixed urban and rural settings, while three focused on urban areas (<a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>; <a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a>), and four on rural areas (<a href="./references#CD013638-bbs2-0003" title="BabuBV , SatyanarayanaK . Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Tropical Doctor2003;33(2):79-82. ">Babu 2003</a>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>). </p> <p>Participant populations had typically received a mean of two or three rounds of MDA at the time of the study. Although five studies, designed to investigate issues surrounding repeat non‐compliance, were conducted after the seventh (<a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a>), 10th (<a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a>), and 15th (<a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>) round of treatment. </p> <p>Combined DEC and albendazole was the most common regimen (15: <a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a>; <a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a>; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a>; <a href="./references#CD013638-bbs2-0013" title="KingJD , Zielinski-GutierrezE , Pa'auM , LammieP . Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Tropica2011;120(Suppl 1):S48-54. ">King 2011</a>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a>; <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>; <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a>), followed by DEC alone (5: <a href="./references#CD013638-bbs2-0003" title="BabuBV , SatyanarayanaK . Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Tropical Doctor2003;33(2):79-82. ">Babu 2003</a>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a>; <a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a>), combined ivermectin and albendazole (7: <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>), and triple‐therapy of albendazole, ivermectin, and DEC (3: <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>).  </p> <p>Community drug distributors (CDDs) supervised by government HCWs were responsible for the distribution in most studies. For <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>, the programme used a combination of CDDs alongside teachers. For the most part, distribution was conducted 'door‐to‐door' except for two studies where it was conducted at local gathering points such as schools (<a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a>), and one study that used a combination of door‐to‐door and local gathering points (<a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a>). </p> <p>Most studies provided education and sensitization as part of their implementation and two studies gave no information (<a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>). </p> <p>Most studies were classified as 'top‐down with limited community involvement', type V using the typology described by <a href="./references#CD013638-bbs2-0120" title="WhiteheadTI . Community based interventions, definitions and types. Cultural Ecology of Health and Change (CEHC) Working Papers Series2002;2:3-4.">Whitehead 2002</a> (<a href="#CD013638-tbl-0002">Table 1</a>). One study was classified as "top‐down with no community involvement" (type VI), as their distribution was via health staff (<a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a>). </p> <p>Twelve studies reported directly observed treatment (DOT) (<a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a>; <a href="./references#CD013638-bbs2-0003" title="BabuBV , SatyanarayanaK . Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Tropical Doctor2003;33(2):79-82. ">Babu 2003</a>; <a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; <a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a>; <a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a>; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a>; <a href="./references#CD013638-bbs2-0013" title="KingJD , Zielinski-GutierrezE , Pa'auM , LammieP . Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Tropica2011;120(Suppl 1):S48-54. ">King 2011</a>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a>), and the remaining 17 did not provide any details (<a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a>; <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a>; <a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>; <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>).  </p> </section> </section> <section id="CD013638-sec-0041"> <h3 class="title" id="CD013638-sec-0041">Assessment of methodological limitations</h3> <p><a href="#CD013638-tbl-0005">Table 4</a> shows a summary of judgements.  </p> <div class="table" id="CD013638-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Methodological limitations appraisal</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Author</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> <p><b>Were steps taken to increase rigour in the sampling?</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Were steps taken to increase rigour in the data collected?</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Were steps taken to increase rigour in the analysis of the data?</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Were the findings of the study grounded in/ supported by the data?</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Please rate the findings of the study in terms of their breadth and depth</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Overall, what weight would you assign to this study in terms of the reliability/trustworthiness of its findings?</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>What weight would you assign to this study in terms of the usefulness of its findings for this review?</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Medium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0003" title="BabuBV , SatyanarayanaK . Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Tropical Doctor2003;33(2):79-82. ">Babu 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth but limited depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0013" title="KingJD , Zielinski-GutierrezE , Pa'auM , LammieP . Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Tropica2011;120(Suppl 1):S48-54. ">King 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/ can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good depth and breadth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth but limited depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Medium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth but limited depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth but limited depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Medium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/ can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth but limited depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth but limited depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium<br/>  </p> </td> </tr> </tbody> </table> </div> <p>The reliability and trustworthiness of the studies was high in six studies (<a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>), medium in seven (<a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; <a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>; <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a>), and low for 16 (<a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a>; <a href="./references#CD013638-bbs2-0003" title="BabuBV , SatyanarayanaK . Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Tropical Doctor2003;33(2):79-82. ">Babu 2003</a>; <a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>; <a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a>; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a>; <a href="./references#CD013638-bbs2-0013" title="KingJD , Zielinski-GutierrezE , Pa'auM , LammieP . Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Tropica2011;120(Suppl 1):S48-54. ">King 2011</a>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a>; <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>). We based this judgement on: the rigour of sampling, which was of medium to high quality with at least several attempts made in nine studies (<a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>; <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a>), a few steps taken to improve rigour in 17 studies (<a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a>; <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0003" title="BabuBV , SatyanarayanaK . Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Tropical Doctor2003;33(2):79-82. ">Babu 2003</a>; <a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>; <a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a>; <a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a>; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a>; <a href="./references#CD013638-bbs2-0013" title="KingJD , Zielinski-GutierrezE , Pa'auM , LammieP . Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Tropica2011;120(Suppl 1):S48-54. ">King 2011</a>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a>; <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a>; <a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>), and three studies did not provide enough information to make a judgement (<a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a>). Rigour of data collection was medium to high quality with at least several attempts made in 12 studies (<a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a>; <a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>), a few steps to preserve rigour in 10 (<a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a>; <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a>; <a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a>; <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a>), seven studies did not provide enough information to make a judgement (<a href="./references#CD013638-bbs2-0003" title="BabuBV , SatyanarayanaK . Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Tropical Doctor2003;33(2):79-82. ">Babu 2003</a>; <a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>; <a href="./references#CD013638-bbs2-0013" title="KingJD , Zielinski-GutierrezE , Pa'auM , LammieP . Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Tropica2011;120(Suppl 1):S48-54. ">King 2011</a>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>); and finally, the rigour of analysis, with only seven studies taking at least several steps to ensure rigour in the data analysis (<a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>; <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a>), and seven taking a few steps (<a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a>; <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; <a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; <a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a>; <a href="./references#CD013638-bbs2-0013" title="KingJD , Zielinski-GutierrezE , Pa'auM , LammieP . Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Tropica2011;120(Suppl 1):S48-54. ">King 2011</a>). Fifteen studies provided insufficient information to make a judgement (<a href="./references#CD013638-bbs2-0003" title="BabuBV , SatyanarayanaK . Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Tropical Doctor2003;33(2):79-82. ">Babu 2003</a>; <a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>; <a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a>; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a>; <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>). </p> <p>The weight in terms of usefulness of the findings for this review was low in 14 studies (<a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a>; <a href="./references#CD013638-bbs2-0003" title="BabuBV , SatyanarayanaK . Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Tropical Doctor2003;33(2):79-82. ">Babu 2003</a>; <a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>; <a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a>; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a>; <a href="./references#CD013638-bbs2-0013" title="KingJD , Zielinski-GutierrezE , Pa'auM , LammieP . Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Tropica2011;120(Suppl 1):S48-54. ">King 2011</a>; <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a>; <a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a>), medium in eight studies (<a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>; <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a>), and high in seven studies (<a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>). We based this judgement on: the grounding of the findings, which was 'good' in only eight studies (<a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>; <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a>), 'fair' in 10 (<a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; <a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a>; <a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>), and 'limited' in 11 (<a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a>; <a href="./references#CD013638-bbs2-0003" title="BabuBV , SatyanarayanaK . Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Tropical Doctor2003;33(2):79-82. ">Babu 2003</a>; <a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a>; <a href="./references#CD013638-bbs2-0013" title="KingJD , Zielinski-GutierrezE , Pa'auM , LammieP . Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Tropica2011;120(Suppl 1):S48-54. ">King 2011</a>; <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a>); and the breadth and depth of findings, which were 'good' for both components for eight studies (<a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>; <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a>), 'fair' for three (<a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a>), and 'limited' for 12 (<a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a>; <a href="./references#CD013638-bbs2-0003" title="BabuBV , SatyanarayanaK . Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Tropical Doctor2003;33(2):79-82. ">Babu 2003</a>; <a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a>; <a href="./references#CD013638-bbs2-0013" title="KingJD , Zielinski-GutierrezE , Pa'auM , LammieP . Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Tropica2011;120(Suppl 1):S48-54. ">King 2011</a>; <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a>). A further six studies had good breadth but limited depth (<a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; <a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>). </p> </section> <section id="CD013638-sec-0042"> <h3 class="title" id="CD013638-sec-0042">Synthesis findings</h3> <p>We sought to describe how programme delivery factors impacted on community perceptions and the decisions to adhere. To do this we collected information on: drug regimen, mechanism of drug distribution, education and sensitization provided, and whether the programme was designed on a 'top‐down' or 'bottom‐up' approach. We briefly described the results of this in the 'study context' section. We found that few studies actually described the design and implementation of their local programme and as a result, most of the information we collected was based on national policy documents or related literature. The consequence of this is that these programme design influences appear nearly identical for most studies, preventing us from generating any meaningful comparisons.  </p> <p>A summary of the themes described below is presented in <a href="./full#CD013638-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD013638-sec-0043"> <h4 class="title">Theme 1: people weigh up benefits and harms before adhering</h4> <p>Synthesis statement: there are many outcomes of taking the drugs, which can be both positive and negative. For community members, several of these may exist at once, and the decision to partake is a careful balance. Competing priorities and existing narratives of disease shape the perception of benefit. Any unpleasant associations, even if only experienced by a few people, rapidly become part of the narrative and spread rapidly through the community, and through social media. </p> <section id="CD013638-sec-0044"> <h5 class="title">Subtheme 1.1: the perceived benefits relate to the relief of suffering, stigma, and costs of disease (high confidence)  </h5> <p>People recognize that MDA can both prevent LF and treat existing infections. When people describe the benefits, they often do so in terms of their felt experience, rather than listing information they have learnt as part of the programme education campaigns. People generally describe these benefits with a sense of relief and gratitude. Three main themes related to benefits emerged. </p> <p><b>Relief from suffering:</b> from a personal perspective, people were relieved that would not be at risk of developing the disease and becoming sick (India: <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; Philippines: <a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a>; Papua New Guinea: <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>; Tanzania: <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; Zambia: <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>; Ghana: <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a>; Fiji: <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>). Some also found some relief in their current symptoms (Tanzania: <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>). At a wider community level,  people were motivated to participate in order to eliminate the disease from the area, they spoke of a greater good in ensuring the entire community was 'happy and healthy': "<i>I have to help my children, grandchildren and great‐grandchildren by taking the drug to uproot the disease from our community</i>" (male opinion leader, Ghana; <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>) (Ghana: <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; India: <a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a>; Tanzania: <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; Dominican Republic: <a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a>). Some remarked how there were fewer people in the community with LF since the start of the programme and this encouraged them to continue taking the drugs (Ghana: <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; Tanzania: <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>). </p> <p><b>Relief from stigma:</b> the physical signs of the disease (i.e. hydrocoele and elephantiasis) is highly stigmatized in the community (Ghana: <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>). People described how they would feel ashamed if they got LF and would anticipate social exclusion (Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; Philippines: <a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a>). In one study, simply being shown pictures of swollen limbs was enough to shock people into compliance (Dominican Republic: <a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a>). As well as personal shame, people spoke of the wider reputation of the area. One man described how "<i>He and his family would feel ashamed and uncomfortable if outsiders saw [their] people with big legs</i>" (young community member, Indonesia; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>). He connected this statement to feeling embarrassed seeing "<i>someone's enlarged genitals on a large film screen in public</i>" referring to sensitization campaigns, and did not want himself or his neighbours to be made an example of. </p> <p><b>Relief from costs:</b> falling sick with LF costs money. People worried about being able to afford operations to manage the morbidity and about how they would support their family if they are unable to work (Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; Philippines: <a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a>): "<i>the risk of getting LF if he did not take the treatment was too costly for him in economic terms; who would pay for his operation? He also felt responsible for the economic livelihood of his household so if he was sick with LF, then he would not be able to provide for his family</i>" (community member, Indonesia; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>). </p> </section> <section id="CD013638-sec-0045"> <h5 class="title">Subtheme 1.2: adverse effects are a frightening and unwelcome experience (high confidence)</h5> <p>When community members talked about AEs, they used words such as 'frightened' or 'afraid'. Many gave vivid accounts of the suffering they experienced and observed from others and explained that for this reason, they were unwilling to adhere (Ghana: <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; India: <a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a>; Tanzania: <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>; Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; Kenya <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>; Papua New Guinea: <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>; Zambia: <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>). One woman from Indonesia described "<i>going to sleep and not waking until the next morning (saying they were unconscious)</i>" (community member, Indonesia; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>). One explained why he had never adhered: "<i>I was afraid of the side effects, I don't want to become weak after taking it or to develop rashes and itches on my body</i> " (CDD, Ghana;<i> </i><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>)<i>.</i> For some, AEs were not only feared, but they could interrupt people's lives and could prevent them from being able to attend work (Ghana: <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>). In one study, people found AEs so upsetting that they attacked the CDDs; "<i>They usually complain and sometimes attack me</i> … <i>because of the reactions or side effects they have after taking the drug</i>" (CDD, Ghana; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>). In contrast, <i>s</i> ome experience the AEs and find them tolerable but still chose not to adhere, suggesting that they were either unaware of the benefits or did not believe they were worth feeling ill for:<i> </i> "<i>I feel really fine and not taking it is also okay. Rather that, than take it too and am dizzy, sleeping, like taking ecstasy, it is better not to bother with it</i> " <i>(</i>community member, Indonesia; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>)<i>.</i> Despite AEs being a serious concern for community members, the experiences were sometimes dismissed by health staff and their impact on adherence undervalued: "<i>[the community] say they were vomiting</i> , <i>and feeling dizzy … but we have not recorded any serious side effects that should scare somebody enough not to take the drug</i>" (Health worker, Ghana; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>).<i> </i> </p> <p>It is already a frightening experience to fall seriously ill after taking an unfamiliar drug. This is heightened when people realize they need urgent medical attention and are unable to access it. Community members may find that MDA staff have left and there is no one around to help (<a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a>): "<i>I would have died if I was not admitted to the head‐quarter hospital during the night after consuming the tablets. There was no one to look after me. After the [health care] worker gave me the medicine, I could not find him again. There was no one in our nearby hospital when I arrived there</i>" (female community member, India; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a>). Those that did find a health worker were sometimes asked to pay for treatment (Ghana: <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>). People living in poor communities may have been unable to afford this treatment and may have decided it is not worth the risk of adherence. When AEs were prewarned and after‐care and monitoring were provided, health staff reported improvements in participation and community members described an increased level of trust in the programme (Ghana: <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a>; Haiti:<i> </i><a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; India: <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; Papua New Guinea: <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>)<i>. </i> </p> </section> <section id="CD013638-sec-0046"> <h5 class="title">Subtheme 1.3: news of adverse effects spreads rapidly and makes people fearful (moderate confidence) </h5> <p>Refusing to adhere to treatment due to AEs was a common finding and further, several studies presented quotes that suggested whole communities, or at least large groups were collectively rejecting treatment: "<i>People are afraid to take these medicines. Something may happen after eating these medicines. So we are not willing to swallow</i>" (male community member, India (<a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>)) (Ghana: <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; India: <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a>). Any occurrence of AEs appeared to become swiftly part of the community narrative of the MDA programme. This meant that people who had never taken the treatment before, or had never personally experienced AEs may not have been willing to take the treatment either. This collective fear of treatment often arose because of rumours and stories that rapidly propagated through media and social networks, causing mass panic. "<i>I remember very well that somewhere in 2008, several children were given the drug and they had serious side effects including rashes, dizziness and swollen faces and legs …, some became very sick. Since then, the news had spread like wildfire, and as a result of that, many people in many communities do not want to take the drug again</i>" (opinion leader, Ghana; <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>) (Ghana:<i> </i><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; India: <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a>; Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; Tanzania: <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>)<i>.</i> If not warned AEs could happen, their occurrence may have strengthened the perception that MDA was harmful and reinforced the distrust people had in the programme. </p> </section> <section id="CD013638-sec-0047"> <h5 class="title">Subtheme 1.4: deciding to adhere draws on personal and shared experiences and is complex (high confidence) </h5> <p>Not every individual experienced benefits, and some may have experienced harms. As a result, the community adhered based on their personal and shared experiences, rather than what was viewed from the global policy level. Further, benefits were interpreted in the context of what people experienced so far. Especially in places where the disease had been around a long time, as people had their own narratives of how the disease was transmitted and what it looked like.  </p> <p>A common belief was that only people with symptoms were infected, and so did not believe that LF was a problem in the area or that they were at risk. They may have recognized some benefits and accepted that the programme was useful to others, but not to them personally: "<i>filariasis does not occur to me, so I have not swallowed. Those who are suffering from filariasis should swallow … why should we swallow?</i>" (male community member, India: <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>) and "<i>There isn't a filarial patient in our house, so it is not going to spread in our home. Two filaria patients in our village are from the same family and as they are residing at the extreme end of the village, the infection will not attack us</i>" (community member, India; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a>) (Ghana: <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; India: <a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; <a href="./references#CD013638-bbs2-0065" title="RamaiahKD , Vijay KumarKN , RaviR , DasPK . Situation analysis in a large urban area of India, prior to launching a programme of mass drug administrations to eliminate lymphatic filariasis. Annals of Tropical Medicine and Parasitology2005;99(3):243-52. ">Ramaiah 2005</a>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; Tanzania: <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>; Kenya: <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>; Papua New Guinea: <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>; Haiti: <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a>). Similarly, in the context of their lives, some did not perceive LF as a problem when compared to malaria, fever, and diarrhoea (India: <a href="./references#CD013638-bbs2-0065" title="RamaiahKD , Vijay KumarKN , RaviR , DasPK . Situation analysis in a large urban area of India, prior to launching a programme of mass drug administrations to eliminate lymphatic filariasis. Annals of Tropical Medicine and Parasitology2005;99(3):243-52. ">Ramaiah 2005</a>; Tanzania: <a href="./references#CD013638-bbs2-0106" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45.">Parker 2013b</a>). </p> <p>People with late‐stage LF were those with the physical conditions of hydrocoele and elephantiasis, they suffered the most from the disease and yet did not benefit from the treatment; "<i>you can't do anything for it when the leg is already big</i> " (community member, Indonesia;<i> </i><a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>). Moreover, the symptoms were what many people tended to associate with 'having LF'. As a result, the community's perception of the effects was influenced by the poor correlation between taking the drug and disease: "<i>Some people don't see any effect in their sickness after taking the drugs. They don't improve and are still sick, even in the leg</i>" (28‐year‐old male farmer, Indonesia; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>) (Tanzania: <a href="./references#CD013638-bbs2-0106" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45.">Parker 2013b</a>; Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; Zambia: <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>). </p> <p>However, their perception of harm was influenced when previously 'healthy' people went on to develop symptoms after being treated. The drugs could induce hydrocoele and elephantiasis in previously asymptomatic people and this led some to think the drugs actually caused LF rather than prevented it (Tanzania: <a href="./references#CD013638-bbs2-0106" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45.">Parker 2013b</a>; Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; Haiti: <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>).  </p> <p>People's understanding of the programme purpose was influenced by their previous experience of similar public health programmes. Some believed the drugs worked like a vaccine, making them immune "<i>they will never get sick with filariasis again in times to come</i>" (community member, Papua New Guinea; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>). As a result, they may have falsely believed they were no longer at risk, and thus refuse subsequent rounds of treatment or question the efficacy when they did go on to develop LF (Papua New Guinea: <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a>; Tanzania: <a href="./references#CD013638-bbs2-0106" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45.">Parker 2013b</a>). </p> <p>Some people had not seen benefits despite years of treatment, LF was still ongoing in the community and they were experiencing treatment fatigue: "<i>The treatment has a hard time killing the worms and healing [LF]. The researchers have to keep taking blood. I don't understand the point of the treatment, there has been treatment since the 80s and there is no change</i>" (41‐year‐old male farmer and community leader, Indonesia; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>) (Tanzania: <a href="./references#CD013638-bbs2-0106" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45.">Parker 2013b</a>; Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>). </p> </section> </section> <section id="CD013638-sec-0048"> <h4 class="title">Theme 2: many people are suspicious of MDA programmes</h4> <p>Synthesis statement: history shapes community attitudes and narratives and fosters this suspicion, although a few in poor communities have complete faith in government. </p> <section id="CD013638-sec-0049"> <h5 class="title">Subtheme 2.1: many people do not trust the programme and believe there is an ulterior motive (high confidence) </h5> <p>Many people do not trust the programme and believe there must be an ulterior motive: "<i>People believe that these drugs have a hidden agenda</i>" (community member, Indonesia; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>) (India: <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; Ghana: <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; Tanzania: <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>; Kenya: <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>; Haiti: <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a>)<i>.</i> Some suspect the true purpose was to collect blood to sell (Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>); or that the drugs were contraceptives (Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; Tanzania: <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; <a href="./references#CD013638-bbs2-0106" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45.">Parker 2013b</a>; Kenya: <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>; Ghana: <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; Haiti: <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a>); or even, in the extreme, that the drugs had been brought to kill them: "<i>Free drugs are brought to kill us. People are afraid to use even the free bed nets provided</i> " (community member, Indonesia;<i> </i><a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>) (Tanzania: <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>;<i> </i> Indonesia:<i> </i><a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>). MDA campaigns are implemented into complex historical and political contexts that ultimately shape how they are received. Without an adequate understanding of why the drugs were distributed, people may have inferred motivation from this sociopolitical context instead. As a result, the trust people have in the programme was often an extension of the trust they had in their government: "<i>you have to trust in the government to swallow the tablets … trust matters a lot. If you don't trust them, you can't swallow the drug</i>" (Tanzania: <a href="./references#CD013638-bbs2-0106" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45.">Parker 2013b</a>). </p> <p>As a result, negative experiences and perceptions of government can harm the credibility of the programme. In one study, people described how their needs had been ignored by the government in the past; they questioned the sudden intent to help, when they were still without anti‐malarials and clean water; "<i>There is something strange going on. If the government want to help us, they should distribute malaria drugs for free, not [elephantiasis and hydrocele]</i>" (young male community member, Tanzania; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>). Others may recall traumatic events. PKI (the Indonesian Communist Party) had distributed free goods as part of their campaign in 1965 and all those in receipt of such items were found guilty by association and murdered. As a result, people are fearful of free gifts: "<i>many have suffered trauma from [outsiders], lots of trauma. If someone comes with a free distribution, they [community] ask me if they are associated with PKI [Indonesian Community Party]. PKI gave free goods, and in the end, we have family who died as a result, they were murdered</i>" (community leader, Indonesia; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>). </p> <p>For some people, these fears could be attributed to colonial legacies<i>.</i> Some community members were aware of the role of western donors in the programme and in some cases, this fuelled their suspicions (Tanzania: <a href="./references#CD013638-bbs2-0106" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45.">Parker 2013b</a>)<i>.</i> For example, some believed the drugs were contraceptives because they know that "<i>white people were fed up giving us help every day</i>" (male community member, Tanzania; <a href="./references#CD013638-bbs2-0106" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45.">Parker 2013b</a>) and that "<i>We know women in Europe have two children and their intention is to make Africans like Europeans. They think we can't manage so many children, that we can't provide proper education, health care and home environment</i>" (community member, Tanzania; <a href="./references#CD013638-bbs2-0106" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45.">Parker 2013b</a>). </p> </section> <section id="CD013638-sec-0050"> <h5 class="title">Subtheme 2.2: some have an unquestioning attitude to government and a lack of agency, leading to unwavering faith in the programme (moderate confidence) </h5> <p>Some community members describe themselves, as 'simple uneducated people', who automatically accept their governments' advice as they believe they know what is best for them: "<i>We don't know – we are little people here so if they give us services, then we accept it; if not, then we sit quietly like this … they know more about the situation in this country, how to advance this country. They know how far the capability is. We, the little people, don't know. They know</i>" (community member, Indonesia; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>). They may have felt grateful to be noticed and helped by their government. They may also have felt a responsibility to make government programmes work and perhaps to be seen as compliant citizens: "<i>So if he doesn't drink, we will direct or persuade him so that he will also take it so that this government programme will have results in 2010</i>" (community member, Indonesia; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>).  </p> </section> </section> <section id="CD013638-sec-0051"> <h4 class="title">Theme 3: programmes expect compliance: this can result in coercion and blame</h4> <p>Synthesis statement: government HCWs, CDDs, and community members can become coercive and blaming as a response to the programme's imperative for compliance. </p> <section id="CD013638-sec-0052"> <h5 class="title">Subtheme 3.1: health workers may become authoritarian to ensure compliance (moderate confidence) </h5> <p>HCWs and CDDs are responsible for the delivery of MDA and perhaps, under pressure to meet programme targets could become demanding (<a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>). For example, in one study, when people spoke about HCW or CDD attitudes, they sometimes described them as "angry" or "shouting" to take the drugs, and to take them quickly (India: <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; Tanzania: <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>). A few were afraid that if they did not take the drugs, HCWs would blame them for falling sick with LF and deny them further treatment: "<i>They will say – the doctor has already come and now you're sick! It's your own fault! You take your own risks. They will not help you if you get sick, you will go to the hospital alone</i>" (female community member, Indonesia; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>)). The husband of one HCW stated that their authoritarian approach was justified "<i>force is necessary, so people will understand</i> " (community member, Indonesia;<i> </i><a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>). It is possible that this directive approach was normalized and the health workers believed it was the obvious solution to the challenge of low compliance in communities. </p> </section> <section id="CD013638-sec-0053"> <h5 class="title">Subtheme 3.2: community members may become coercive, and stigmatize non‐compliance (moderate confidence) </h5> <p>In one study, some members of the community also dealt with non‐compliance from neighbours similarly: perhaps taking their lead from the behaviour displayed by HCWs and CDDs. While HCWs and CDDs were likely under pressure to meet compliance demands, coercive behaviour by community members appeared to be fuelled by genuine fears of LF persisting in the community and putting others at risk, or the financial and physical burden of having to take care of a sick neighbour or family member: "<i>If she's sick, everyone has to think about helping her. Everyone's burdened. If she doesn't want to take the drug, what can we do? Force? If there is someone who refuses, and they get sick, the neighbours can come and yell and force her to take it</i>" (male community member, Indonesia; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>) (Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>). In contrast to subtheme 3.1, people were not only blamed for falling sick but for harming everyone else and so people justified coercion in order to protect themselves and their families. This may have been in the form of aggression as described above; shaming: "<i>all will ridicule her at the time</i> "; or by shunning them from the rest of the community: "<i>she can be fenced in, not allowed to live with family, she would be expelled so that this disease could not breed</i>" (community leader, Indonesia; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>) (Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>).  </p> <p>When people were asked how they would react to a non‐complier, there were cases insisting that the decision was up to the individual and they would not be forced. It may have been that the coercion and stigmatization of non‐adherence observed varied between communities and countries. However, in one example, the respondent simultaneously described how they did not use force, but then went on to explain how they <i>would</i> pressure the woman to concede: "<i>We won't force her, but if we show her the right way again and again, for sure she will think, ya, I want to follow too</i> " (female community member, Indonesia;<i> </i><a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>,) suggesting that perhaps coercive behaviour is so normalized during distribution that people did not even realize they were doing it<i>.</i> </p> </section> <section id="CD013638-sec-0054"> <h5 class="title">Subtheme 3.3: outward compliance, private rejection (moderate confidence)</h5> <p>While the 'official' public narrative is high rates of adherence to the drugs, there were instances where people appeared to comply, and privately reject (Ghana: <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>)<i>:</i> "<i>Many people she knew hid the medication when asked to take it in front of the health official, drinking water only instead of swallowing the medication, which they threw away later</i>" (female community member, Indonesia; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>. People may have pretended to be pregnant or breastfeeding to be exempt from treatment (Ghana: <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>). These examples represent a strong rejection of both the treatment and the authority promoting it, and may have further eroded the trust between programme and participants. CDDs also had a role in this facade as "<i>some of [them] will throw some of the medicine away and then mark people in the register as having received the medicine just to show that [they] are hardworking</i>" (female distributor, Ghana; <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>) (Ghana: <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; Kenya: <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>). Some people described how the CDD "<i>will give you the drug and it is left to you to take it or refuse</i>" (female opinion leader, Ghana; <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>) (Ghana: <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>). This evades the social pressure of adherence described above and allows families to make a personal decision: "<i>the choice of taking drugs will remain to be of the household head and even the community members want it that way because they think that is what is best</i> " (village elder, Kenya;<i> </i><a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a>). </p> </section> </section> <section id="CD013638-sec-0055"> <h4 class="title">Theme 4: distributor's status in the community is often low, and they are not well‐equipped to answer the communities' questions </h4> <p>Synthesis statement: they have little authority, and the behaviour of some damages the MDA programme's reputation. Communities want information about programmes to help make decisions about participation, but drug distributors are not sufficiently informed, or skilled in this communication. </p> <section id="CD013638-sec-0056"> <h5 class="title">Subtheme 4.1: community drug distributors have limited authority (moderate confidence)</h5> <p>CDDs hold no formal qualifications or titles and so are not perceived as part of the health system. Yet, they are placed in a position to demand people take treatment and are expected to answer complex health questions. As a result, they have a muddled role in the distribution that leads people reject their involvement. Their lack of formal qualifications or status means people did not trust that they were being given correct advice: "<i>He disapproved of the community health worker … claiming that she was too poorly educated to be credible</i>" (community member, Indonesia; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>) (Tanzania: <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; India: <a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a>; <a href="./references#CD013638-bbs2-0065" title="RamaiahKD , Vijay KumarKN , RaviR , DasPK . Situation analysis in a large urban area of India, prior to launching a programme of mass drug administrations to eliminate lymphatic filariasis. Annals of Tropical Medicine and Parasitology2005;99(3):243-52. ">Ramaiah 2005</a>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>). In addition, some people argued that if the drugs were so important, their doctor would have already informed them (India: <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; Kenya: <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>). As a result, some people rejected treatment, while others refused to engage until their doctor had given them permission (Tanzania: <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; India: <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a>; <a href="./references#CD013638-bbs2-0065" title="RamaiahKD , Vijay KumarKN , RaviR , DasPK . Situation analysis in a large urban area of India, prior to launching a programme of mass drug administrations to eliminate lymphatic filariasis. Annals of Tropical Medicine and Parasitology2005;99(3):243-52. ">Ramaiah 2005</a>; Kenya: <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>). Further, the limited authority that community members did have could sometimes have the opposite effect; people were sometimes offended that CDDs were 'acting like health workers', in effect, above their station and: "<i>they come to order all of us about as if they are our doctors. I think that the doctors should have a meeting with us and tell them in our presence that they are under us for us to supervise them</i>" (male community leader, Ghana; <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>) (Ghana: <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>).  </p> <p>Despite also not having medical training, community or religious leaders do possess authority in their communities and their instruction is perhaps trusted more than that of CDDs (Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; Kenya: <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; Zambia: <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>). One man explained how "<i>an American missionary pastor told him that when he was sick, he should take traditional medicine and since then, he had followed his advice</i>" (older male community member, Indonesia; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>). As a result, CDDs that are chosen by or endorsed by community leaders may elicit greater trust and co‐operation (Ghana: <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>: Kenya: <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>).  </p> </section> <section id="CD013638-sec-0057"> <h5 class="title">Subtheme 4.2: people prefer community drug distributors that are well known to the community and have good behaviour (high confidence) </h5> <p>As explored in theme 2 (many people are suspicious of MDA programmes), people can be suspicious of interventions imposed on them from external agents. Therefore, some reported they were motivated to adhere when their CDDs were known by them and came from the same community. Some explained that they participated in MDA specifically because of their relationship to their distributor (India: <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a>; Tanzania: <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; Kenya: <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>; Zambia: <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>). In contrast, some reported various instances of CDDs behaving inappropriately (examples included demanding money or gifts, drinking too much alcohol, or arguing about politics) and that they refused the drugs on this basis (Ghana: <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>). "<i>Personally, I don't take the medicine every year because I just don't like the distributor in this community</i>" (male opinion leader, Ghana; <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>). In all, this demonstrates how integral the perception of CDDs is on the success of the programme. </p> </section> <section id="CD013638-sec-0058"> <h5 class="title">Subtheme 4.3: people seek clarification and rationale, but do not always receive it (high confidence) </h5> <p>Communities with long‐standing LF often have their own well‐established narratives about the disease, which means any rationale for MDA needs to be compatible with this. People could and did choose to incorporate public health information into their traditional narratives and participate in the programme (India: <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a>; Ghana: <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>). However, as one man explained how "<i>for him, traditional medicine and LF medicine had the same use—to prevent disease and keep him healthy. He planned to continue using traditional medicine so that he would not get sick from LF</i>" (community member, Indonesia; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>). This man accepted the public health knowledge given to him as it reflected his own reason for taking traditional treatment. But the rationale given for MDA did not make sense in the context of his own experience – he already had an effective treatment. The different community knowledge on LF, the varying quality of education campaigns, and the problems communities had in integrating their own knowledge with what was being said to them meant people had questions (Kenya: <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a>; <a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a>; India: <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; Tanzania: <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a>; Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>). <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a> provided a list of questions commonly asked during their study and we found that they typically reflected community concerns explored in earlier themes. For example, some people were confused why they needed to take the drugs even though they felt well; and were concerned why people went on to develop symptoms of elephantiasis and hydrocoele after treatment (subtheme 1.4: the decision to adhere is complex and based on personal and shared experiences so far). Others questioned why "E<i>uropeans [are] manufacturing tablets for [elephantiasis and hydrocoele] when they do not suffer from these diseases?</i> (community member, Indonesia; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>) (theme 2: many people are suspicious of MDA programmes). </p> <p>CDDs possessed mainly procedural knowledge on the rules of programme delivery, but were sometimes unable to explain things to the community. "<i>I took the medications for about three times and stopped because the distributors were not telling us why we should continue to take the medicine</i>" (male opinion leader, Ghana; <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>)<i>.</i> In one study, despite having received training on the causes of LF, distributors had a varied understanding of transmission, for example: "<i>From what I learned in school, it is transmitted by mosquitoes, but we were not told so in this MDA"</i> (community member, Tanzania; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>) and "<i>Elephantiasis is a disease which a person gets from worms that are found in the water. The person gets the disease by entering into the water and being bitten by insects living in the water with worm</i>" (CDD, Tanzania; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>). This may have reflected inadequate training and communication between programme implementers and an important group of stakeholders. CDDs were the main interface between programme and community, any distortion at this level was bound to result in misunderstandings and lack of appropriate knowledge. Furthermore, in one study, the community leader intentionally withheld biomedical explanations from the villagers as he assumed they would not understand (Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>). In all, this lack of common understanding led to frustration at the community level as they did not have enough details to make an informed decision (Ghana: <a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a>; India: <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a>; <a href="./references#CD013638-bbs2-0065" title="RamaiahKD , Vijay KumarKN , RaviR , DasPK . Situation analysis in a large urban area of India, prior to launching a programme of mass drug administrations to eliminate lymphatic filariasis. Annals of Tropical Medicine and Parasitology2005;99(3):243-52. ">Ramaiah 2005</a>; Tanzania: <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a>; <a href="./references#CD013638-bbs2-0106" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45.">Parker 2013b</a>; Indonesia: <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>; Kenya: <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a>; <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a>; <a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a>). In one study in Ghana, social mobilization and education resulted in increased willingness to participate in future campaigns (<a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a>). </p> </section> </section> </section> <section id="CD013638-sec-0059"> <h3 class="title" id="CD013638-sec-0059">Confidence in the findings</h3> <p>Based on the CERQual assessment, we graded six subthemes as high confidence and six subthemes as moderate confidence. <a href="./full#CD013638-tbl-0001">summary of findings Table 1</a> shows a summary of the CERQual assessment and the full assessment including individual justifications is detailed in <a href="./appendices#CD013638-sec-0072">Appendix 3</a>. We found the process of considering coherence, including describing and explaining divergent cases, made for stronger theory and two subthemes were dissolved and merged as a result of this. </p> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013638-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013638-sec-0060"></div> <section id="CD013638-sec-0061"> <h3 class="title" id="CD013638-sec-0061">Summary of findings</h3> <p>This review sought the views and experiences of community members, which is often absent from the analysis of vertical programmes. We conducted a QES using thematic analysis and generated four themes:  </p> <p> <ul id="CD013638-list-0009"> <li> <p>people weigh up benefits and harms before adhering; </p> </li> <li> <p>many people are suspicious of MDA programmes; </p> </li> <li> <p>programmes expect compliance: this can result in coercion and blame; and </p> </li> <li> <p>distributor's status in the community is often low, and they are not well‐equipped to answer the communities' questions. </p> </li> </ul> </p> <p>The conceptual model below summarizes the findings of this review (<a href="#CD013638-fig-0003">Figure 3</a>). Our analysis found important links between individual behaviour and the wider community, and to policies and reputations of programmes and organizations, it was easier to visualize factors of influence being nested in an ecological model inspired by Bronfenbrenner's Ecological Systems Theory (<a href="./references#CD013638-bbs2-0081" title="BronfenbrennerU . Ecological systems theory. Annals of Child Development1989;6:187-249.">Bronfenbrenner 1989</a>). This model builds on the conceptual framework developed in the protocol (<a href="./references#CD013638-bbs2-0125" title="TaylorM , OliverS , GarnerP . Mass drug administration for filariasis: community views and programme design influences ‐ a qualitative evidence synthesis. Cochrane Database of Systematic Reviews2020, Issue 6. Art. No: CD013638. [DOI: 10.1002/14651858.CD013638]">Taylor 2020</a>), and included in the <a href="#CD013638-sec-0009">Background</a> (<a href="#CD013638-fig-0001">Figure 1</a>) to demonstrate how several additional factors such as historical and political contexts, competing narratives of disease, social pressures, and sufficiency of information and education impact adherence. It also demonstrates how interventions are not implemented into naive populations and instead interact with pre‐existing multi‐layered narratives and challenges that policymakers could consider when designing and implementing these programmes.  </p> <div class="figure" id="CD013638-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Updated conceptual model demonstrating the wider social, historical, and political influences that shape the experience of the programme and ultimately the decision to adhere." data-id="CD013638-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013638.pub2/media/CDSR/CD013638/image_n/nCD013638-FIG-03.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Updated conceptual model demonstrating the wider social, historical, and political influences that shape the experience of the programme and ultimately the decision to adhere. </p> </div> </div> </div> <p>The review authors were careful to draw out examples of positive perspectives associated with the programme, yet found the overall narrative in the primary research to be predominantly negative. The qualitative literature summarized here foregrounds community views and experiences that are currently missing from policy documents and decisions and could be used to inform programme design and delivery. We are not evaluating the public health effectiveness of programmes and the stated successes in achieving elimination and reduced transmission in many countries to date. However, despite the claims of success from donors, it may be a good time to pause and reflect on lessons to learn from the 48 countries that remain endemic and the communities that continue to be affected by LF despite more than 10 years of treatment (<a href="./references#CD013638-bbs2-0124" title="World Health Organization. Global Programme to Eliminate Lymphatic Filariasis: progress report, 2020. www.who.int/publications/i/item/who-wer9641-497-508 (accessed 19 December 2021).">WHO 2020</a>); well beyond the five years recommended by the WHO. The effectiveness of MDA programmes is a contested area and debates in recent years have questioned the international rhetoric of success compared to the apparent failures at community level (<a href="./references#CD013638-bbs2-0107" title="ParkerM , AllenT . De-politicizing parasites: reflections on attempts to control the control of neglected tropical diseases. Medical Anthropology2014;33(3):223-39.">Parker 2014</a>; <a href="./references#CD013638-bbs2-0108" title="ReiszM . Unwanted side-effects. www.timeshighereducation.com/features/unwanted-side-effects/2004130.article (accessed prior to 20 January 2021).">Reisz 2013</a>). </p> <p> We had intended to analyze the findings in accordance with aspects of programme design and delivery, to see what components influenced community views and in what way. However, there was too little detail in the information we collected to allow for any meaningful comparison. </p> <p>AE were the most frequently mentioned topic. With LF, this is not an intrinsic effect of the drug, but the result of the drug killing microfilaraemia causing fever, headaches, malaise, and muscle pain as a result of the antigen release. We know AEs may be relatively uncommon in MDA programmes as much of the population is uninfected, but even small rates of AEs result in enough cases to generate fear in communities and refusal of treatment. Furthermore, 'mild' AEs (such as fever and nausea; <a href="./references#CD013638-bbs2-0098" title="LimaAW , MedeirosZ , SantosZC , CostaGM , BragaC . Adverse reactions following mass drug administration with diethylcarbamazine in lymphatic filariasis endemic areas in the Northeast of Brazil. Revista de Sociedade Brasileira de Medicina Tropical2012;45(6):745-50.">Lima 2012</a>) may still prevent individuals from being able to work or go about their daily lives and this is more important to them than any perceived benefit. The findings of this review indicate that policymakers may wish to consider that communities are informed about these AEs prior to distribution and to ensure that appropriate after‐care is provided. This helps foster more trust in the programmes. </p> </section> <section id="CD013638-sec-0062"> <h3 class="title" id="CD013638-sec-0062">Overall completeness and applicability of the evidence</h3> <p>The studies encompassed a wide range of countries and were predominantly based on community members of both genders, in both urban and rural settings. </p> <p><a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a> contributed substantially to the coded quotations. This is a PhD thesis conducted in Indonesia. Most of the other studies were conducted in India. However, the studies conducted in Africa were consistent with the broad themes identified, indicating the themes documented by <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a> and others in South‐East Asia about this global programme are applicable in the main regions covered by the global elimination programme. </p> <p>The findings are based on studies conducted in areas of known low compliance and five studies were conducted in areas that had received seven, 10, or 15 rounds of MDA. As a result, the views described may not reflect those of communities with high levels of compliance. However, given how widespread compliance challenges are, the findings of this review make a valid contribution to understanding how some communities perceive MDA programmes. </p> <p>The number of studies meeting the inclusion criteria has increased over 2019 to 2021; we identified 16 studies prior to 2019 and eight studies after 2019. This reflects an increased interest and importance placed on successful MDA campaigns since 2000 with the implementation of GPELF. We conducted a search update in April 2021 as more than one year had passed since we conducted the original search. The findings that emerged from this additional data set broadly supported the findings we had originally, and there were no new themes. We did note however that, for some more‐recent studies (<a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a>), community knowledge and acceptance was increased, and the primary study authors related this to education and sensitization initiatives and provision of AE after‐care.  </p> <p>The PhD thesis we included was detailed (<a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a>). Although not published in peer‐reviewed publications, the quality assessment on this study scored high. In addition, two studies have been published using data originally reported by the thesis, and so we had no concerns about the inclusion of this study in our analysis. </p> </section> <section id="CD013638-sec-0063"> <h3 class="title" id="CD013638-sec-0063">Agreements and disagreements with other studies</h3> <p>The current global guideline for LF states that MDA is an acceptable intervention (<a href="./references#CD013638-bbs2-0122" title="World Health Organization. GUIDELINE Alternative mass drug administration regimens to eliminate lymphatic filariasis. apps.who.int/iris/bitstream/handle/10665/259381/9789241550161-eng.pdf (accessed 13 December 2021).">WHO 2017</a>). However, our findings indicate that for many people, this is not the case. </p> <p>This review found that communities are often suspicious of MDA programmes and may believe the drugs have been brought to kill them or to act as contraceptives. This was supported by two reviews on MDA for LF by <a href="./references#CD013638-bbs2-0092" title="KrentelA , FischerPU , WeilGJ . A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2013;7(11):e2447.">Krentel 2013</a> and <a href="./references#CD013638-bbs2-0074" title="AmesHM , ZuskeM , KingJD , SteinmannP , Bosch-CapblanchX . Community and drug distributor perceptions and experiences of mass drug administration for the elimination of lymphatic filariasis: a rapid review of qualitative research. Advances in Parasitology2019;103:117-49.">Ames 2019</a>. Similar suspicions have also been described for MDA programmes for schistosomiasis and soil‐transmitted helminths (<a href="./references#CD013638-bbs2-0088" title="HastingsJ . Rumours, riots and the rejection of mass drug administration for the treatment of schistosomiasis in Morogoro, Tanzania. Journal of Biosocial Sciences2016;48(Suppl 1):S16-39.">Hastings 2016</a>; <a href="./references#CD013638-bbs2-0094" title="Legge H, Kepha S, Prochazka M, Halliday K, Pullan R, Gwayi-ChoreM , et al. Implementer and recipient perspectives of community-wide mass drug administration for soil-transmitted helminths in Kwale County, Kenya. PLoS Neglected Tropical Diseases2020;14(4):e0008258.">Legge 2020</a>; <a href="./references#CD013638-bbs2-0105" title="ParkerM , AllenT . Does mass drug administration for the integrated treatment of neglected tropical diseases really work? Assessing evidence for the control of schistosomiasis and soil-transmitted helminths in Uganda. Health Research Policy and Systems2011;9:3.">Parker 2011</a>). Poor perceptions and experiences of government and international involvement may fuel these assumptions. <a href="./references#CD013638-bbs2-0105" title="ParkerM , AllenT . Does mass drug administration for the integrated treatment of neglected tropical diseases really work? Assessing evidence for the control of schistosomiasis and soil-transmitted helminths in Uganda. Health Research Policy and Systems2011;9:3.">Parker 2011</a> reported this in their findings and a study by <a href="./references#CD013638-bbs2-0099" title="LowesS , MonteroE . The legacy of colonial medicine in Central Africa. 25 February 2018. scholar.harvard.edu/files/emontero/files/lowes_montero_colonialmedicine.pdf (accessed 1 December 2019).">Lowes 2018</a> described how those in with a greater historical exposure to French‐colonial campaigns to prevent sleeping sickness were more likely to refuse a free, non‐invasive blood test.  </p> <p>Perception of benefit, need, or risk as a motivator towards adherence is well‐supported in the literature (<a href="./references#CD013638-bbs2-0074" title="AmesHM , ZuskeM , KingJD , SteinmannP , Bosch-CapblanchX . Community and drug distributor perceptions and experiences of mass drug administration for the elimination of lymphatic filariasis: a rapid review of qualitative research. Advances in Parasitology2019;103:117-49.">Ames 2019</a>; <a href="./references#CD013638-bbs2-0092" title="KrentelA , FischerPU , WeilGJ . A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2013;7(11):e2447.">Krentel 2013</a>; <a href="./references#CD013638-bbs2-0094" title="Legge H, Kepha S, Prochazka M, Halliday K, Pullan R, Gwayi-ChoreM , et al. Implementer and recipient perspectives of community-wide mass drug administration for soil-transmitted helminths in Kwale County, Kenya. PLoS Neglected Tropical Diseases2020;14(4):e0008258.">Legge 2020</a>; <a href="./references#CD013638-bbs2-0110" title="ShufordKV , TurnerHC , AndersonRM . Compliance with anthelmintic treatment in the neglected tropical diseases control programmes: a systematic review. Parasites &amp; Vectors2016;9:29.">Shuford 2016</a>). This study noted that MDA may not be as prioritized as other concerns such as malaria or access to clean water. <a href="./references#CD013638-bbs2-0088" title="HastingsJ . Rumours, riots and the rejection of mass drug administration for the treatment of schistosomiasis in Morogoro, Tanzania. Journal of Biosocial Sciences2016;48(Suppl 1):S16-39.">Hastings 2016</a>, <a href="./references#CD013638-bbs2-0111" title="SilumbweA , ZuluJM , HalwindiH , JacobsC , ZgamboJ , DambeR , et al. A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa. BMC Public Health2017;17(1):484.">Silumbwe 2017</a>, and <a href="./references#CD013638-bbs2-0078" title="BhullarN , MaikereJ . Challenges in mass drug administration for treating lymphatic filariasis in Papua, Indonesia. Parasites &amp; Vectors2010;3:70.">Bhullar 2010</a> all remarked that worm infections are to some 'just part of life', and that communities describe a sense of bewilderment that LF control is given at the expense of interventions for diseases such as malaria and cholera, which cause high mortality, particularly for their children. This review found that many people do not adhere to treatment because they are afraid of the potential AEs. These findings are supported by several reviews who described AEs as one of the main reasons for non‐compliance (<a href="./references#CD013638-bbs2-0074" title="AmesHM , ZuskeM , KingJD , SteinmannP , Bosch-CapblanchX . Community and drug distributor perceptions and experiences of mass drug administration for the elimination of lymphatic filariasis: a rapid review of qualitative research. Advances in Parasitology2019;103:117-49.">Ames 2019</a>; <a href="./references#CD013638-bbs2-0076" title="BabuBV , BabuGR . Coverage of, and compliance with, mass drug administration under the programme to eliminate lymphatic filariasis in India: a systematic review. Transactions of the Royal Society of Tropical Medicine and Hygiene2014;108(9):538-49.">Babu 2014</a>; <a href="./references#CD013638-bbs2-0092" title="KrentelA , FischerPU , WeilGJ . A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2013;7(11):e2447.">Krentel 2013</a>; <a href="./references#CD013638-bbs2-0110" title="ShufordKV , TurnerHC , AndersonRM . Compliance with anthelmintic treatment in the neglected tropical diseases control programmes: a systematic review. Parasites &amp; Vectors2016;9:29.">Shuford 2016</a>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a>). These concerns have also been reported in control programmes for onchocerciasis (<a href="./references#CD013638-bbs2-0110" title="ShufordKV , TurnerHC , AndersonRM . Compliance with anthelmintic treatment in the neglected tropical diseases control programmes: a systematic review. Parasites &amp; Vectors2016;9:29.">Shuford 2016</a>), soil‐transmitted helminths (<a href="./references#CD013638-bbs2-0094" title="Legge H, Kepha S, Prochazka M, Halliday K, Pullan R, Gwayi-ChoreM , et al. Implementer and recipient perspectives of community-wide mass drug administration for soil-transmitted helminths in Kwale County, Kenya. PLoS Neglected Tropical Diseases2020;14(4):e0008258.">Legge 2020</a>; <a href="./references#CD013638-bbs2-0105" title="ParkerM , AllenT . Does mass drug administration for the integrated treatment of neglected tropical diseases really work? Assessing evidence for the control of schistosomiasis and soil-transmitted helminths in Uganda. Health Research Policy and Systems2011;9:3.">Parker 2011</a>), and schistosomiasis (<a href="./references#CD013638-bbs2-0105" title="ParkerM , AllenT . Does mass drug administration for the integrated treatment of neglected tropical diseases really work? Assessing evidence for the control of schistosomiasis and soil-transmitted helminths in Uganda. Health Research Policy and Systems2011;9:3.">Parker 2011</a>). </p> <p><a href="./references#CD013638-bbs2-0074" title="AmesHM , ZuskeM , KingJD , SteinmannP , Bosch-CapblanchX . Community and drug distributor perceptions and experiences of mass drug administration for the elimination of lymphatic filariasis: a rapid review of qualitative research. Advances in Parasitology2019;103:117-49.">Ames 2019</a> briefly noted that health workers may 'exert some pressure' on people who refused to adhere. However, the use of coercion by health workers and community members is not discussed in detail or elsewhere in the literature relating to MDA programmes. </p> <p>The review identified problems regarding perception of distributors and sufficiency of information provided to the community. <a href="./references#CD013638-bbs2-0074" title="AmesHM , ZuskeM , KingJD , SteinmannP , Bosch-CapblanchX . Community and drug distributor perceptions and experiences of mass drug administration for the elimination of lymphatic filariasis: a rapid review of qualitative research. Advances in Parasitology2019;103:117-49.">Ames 2019</a>, <a href="./references#CD013638-bbs2-0097" title="LieseB , RosenbergM , SchratzA . Programmes, partnerships, and governance for elimination and control of neglected tropical diseases. Lancet2010;375(9708):67-76.">Liese 2010</a>, and <a href="./references#CD013638-bbs2-0111" title="SilumbweA , ZuluJM , HalwindiH , JacobsC , ZgamboJ , DambeR , et al. A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa. BMC Public Health2017;17(1):484.">Silumbwe 2017</a> also described how inadequate training, motivation, and knowledge of distributors negatively impacted adherence. <a href="./references#CD013638-bbs2-0092" title="KrentelA , FischerPU , WeilGJ . A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2013;7(11):e2447.">Krentel 2013</a> noted how familiarity with distributors establishes trust and improves adherence. However, <a href="./references#CD013638-bbs2-0074" title="AmesHM , ZuskeM , KingJD , SteinmannP , Bosch-CapblanchX . Community and drug distributor perceptions and experiences of mass drug administration for the elimination of lymphatic filariasis: a rapid review of qualitative research. Advances in Parasitology2019;103:117-49.">Ames 2019</a> noted that while this may work in small communities, it does not work in larger ones because the likelihood of knowing the distributor is reduced. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013638-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/media/CDSR/CD013638/urn:x-wiley:14651858:media:CD013638:CD013638-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Conceptual model of the driving and restraining influences on MDA delivery and adherence. AE: adverse effect; LF: lymphatic filariasis; MDA: mass drug administration." data-id="CD013638-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013638.pub2/media/CDSR/CD013638/image_n/nCD013638-FIG-01.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Conceptual model of the driving and restraining influences on MDA delivery and adherence. AE: adverse effect; LF: lymphatic filariasis; MDA: mass drug administration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/full#CD013638-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/media/CDSR/CD013638/image_n/nCD013638-FIG-01.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013638-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/media/CDSR/CD013638/urn:x-wiley:14651858:media:CD013638:CD013638-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD013638-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013638.pub2/media/CDSR/CD013638/image_n/nCD013638-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/media/CDSR/CD013638/image_t/tCD013638-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/full#CD013638-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/media/CDSR/CD013638/image_n/nCD013638-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013638-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/media/CDSR/CD013638/urn:x-wiley:14651858:media:CD013638:CD013638-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Updated conceptual model demonstrating the wider social, historical, and political influences that shape the experience of the programme and ultimately the decision to adhere." data-id="CD013638-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013638.pub2/media/CDSR/CD013638/image_n/nCD013638-FIG-03.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Updated conceptual model demonstrating the wider social, historical, and political influences that shape the experience of the programme and ultimately the decision to adhere. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/full#CD013638-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/media/CDSR/CD013638/image_n/nCD013638-FIG-03.jpg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013638-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> <p><b>Theme</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Subtheme</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Studies with information giving rise to the evidence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CERQual rating</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Explanation of CERQual rating </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1: people weigh up benefits and harms before adhering</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1: the perceived benefits relate to the relief of suffering, stigma, and costs of disease </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a><sup>b</sup>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a><sup>d</sup>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a><sup>c,f,g,h,i</sup>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a><sup>k</sup>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coherence, adequacy, and relevance: no or very minor concerns</p> <p>Methodological limitations: minor concerns </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2: adverse effects are a frightening and unwelcome experience</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a><sup>a</sup>;<a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a><sup>c,f,g,h,i</sup>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a><sup>k</sup>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coherence, adequacy, and relevance: no or very minor concerns</p> <p>Methodological limitations: minor concerns</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3: news of adverse effects spreads rapidly and makes people fearful</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a><sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relevance: no or very minor concerns</p> <p>Coherence, adequacy, and methodological limitations: minor concerns</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4: deciding to adhere draws on personal and shared experiences and is complex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a><sup>c,f,g,h,i</sup>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a><sup>k</sup>; <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a><sup>i</sup>; <a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coherence, adequacy, and relevance: no or very minor concerns</p> <p>Methodological limitations: minor concerns</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2: many people are suspicious of MDA programmes</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1: many people do not trust the programme and believe there is an ulterior motive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a><sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High confidence<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coherence, relevance, and adequacy: no or very minor concerns</p> <p>Methodological limitations: minor concerns </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2: some have an unquestioning attitude to government and a lack of agency, leading to unwavering faith in the programme </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methodological limitations: no or minor concerns </p> <p>Coherence, relevance and adequacy: moderate concerns</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3: programmes expect compliance: this can result in coercive and blaming delivery</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1: health workers may become authoritarian to ensure compliance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coherence: no or very minor concerns</p> <p>Adequacy, relevance, and methodological limitations: minor concerns</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2: community members may become coercive, and stigmatize non‐compliance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coherence and methodological limitations: no or very minor concerns</p> <p>Relevancy and adequacy: minor concerns </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3: outward compliance, private rejection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a><sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relevance: no or very minor concerns</p> <p>Coherence, adequacy, and methodological limitations: minor concerns </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4: distributor's status in the community is often low, and they are not well‐equipped to answer the communities questions </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 4.1: CDDs have limited authority</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup>; <a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a><sup>c,f,g,h,i</sup>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a><sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequacy and relevance: no or very minor concerns</p> <p>Coherence and methodological limitations: minor concerns</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2: people prefer CDDs that are well known to the community and have good behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a><sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coherence, adequacy, and relevance: no or very minor concerns</p> <p>Methodological limitations: minor concerns </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3: people seek clarification and rationale, but do not always receive it</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a><sup>c</sup>; <a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a><sup>f</sup>; <a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a><sup>a</sup>; <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a><sup>j</sup>; <a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a><sup>e</sup>; <a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> High confidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coherence, adequacy, and relevance: no or very minor concerns</p> <p>Methodological limitations: minor concerns</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CDD: community drug distributor.<br/><sup>a</sup>Ghana; <sup>b</sup>Philippines; <sup>c</sup>India; <sup>d</sup>Dominican Republic; <sup>e</sup>Tanzania; <sup>f</sup>Indonesia; <sup>g</sup>Papua New Guinea; <sup>h</sup>Fiji; <sup>i</sup>Haiti; <sup>j</sup>Kenya; <sup>k</sup>Zambia. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/full#CD013638-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013638-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Types of delivery in mass drug administration (MDA) programmes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Form of delivery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Approach</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Programs in which individuals or groups/organizations indigenous to the community to be served by a program (target community) initiate, without any external (to that community) support". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bottom‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Programs in which individuals or community groups/organizations groups/ organizations indigenous to the community initiate, and recruit external, technical (expertise) support". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bottom‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Programs in which individuals or community‐based community based organizations (CBOs) pursue external fiscal support or funding". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bottom‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Programs in which individuals or CBOs indigenous to the target community initiate and recruit external technical and fiscal support". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bottom‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Programs which are initiated by external change agencies (public or private organization, university, a corporation, a foundation or some other philanthropic group, and so on) within a target community, but [are done] does it without any input from individual residents or organizations of that community, except as program recipients". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Top‐down</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type VI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Programs which are planned and initiated by external change agencies, and community members are eventually invited to participate on community advisory committees, or as lower‐level lower level project staff such as 'community "community outreach workers', workers", or as volunteers". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Top‐down</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type VII</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Programs which are planned and implemented as an equitable partnership by CBOs and an external change agent or technical organization". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Collaborative</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Amended from <a href="./references#CD013638-bbs2-0120" title="WhiteheadTI . Community based interventions, definitions and types. Cultural Ecology of Health and Change (CEHC) Working Papers Series2002;2:3-4.">Whitehead 2002</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Types of delivery in mass drug administration (MDA) programmes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/full#CD013638-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013638-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of review studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Author</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Aims</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Methods</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Inclusion criteria</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of studies</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0076" title="BabuBV , BabuGR . Coverage of, and compliance with, mass drug administration under the programme to eliminate lymphatic filariasis in India: a systematic review. Transactions of the Royal Society of Tropical Medicine and Hygiene2014;108(9):538-49.">Babu 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"To systematically review published studies on the coverage of and compliance with MDA under the Programme for the Elimination of Lymphatic Filariasis (PELF) in India". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quantitative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013638-list-0001"> <li> <p>Up to 2013</p> </li> <li> <p>India</p> </li> <li> <p>Quantitative studies and quantitative data that can be extracted from mixed‐methods studies </p> </li> <li> <p>"Community based studies that evaluated MDA coverage and compliance conducted by the health services. Data were excluded if governmental, non‐governmental or research organizations intervened to improve compliance. However, papers that reported such studies were considered and data on control MDAs were included". </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0111" title="SilumbweA , ZuluJM , HalwindiH , JacobsC , ZgamboJ , DambeR , et al. A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa. BMC Public Health2017;17(1):484.">Silumbwe 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"To systematically document the barriers and facilitators to implementation of MDA for LF in Sub‐Saharan Africa". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed‐methods:</p> <p>qualitative (3 studies); quantitative (4 studies); mixed methods (4 studies); programme reports (6 studies); evaluation (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013638-list-0002"> <li> <p>2000–2016</p> </li> <li> <p>Sub‐Saharan Africa</p> </li> <li> <p>Studies that assessed the following outcomes: "(i) treatment coverage/compliance, (ii) program sustainability, (iii) successful implementation referring to perceptions among implementation stakeholders (both provider and community) that a given treatment, service, practice, or innovation is agreeable, palatable, or satisfactory with their needs, and (iv) community participation, defined as the involvement of the community in programme design implementation and evaluation". </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0092" title="KrentelA , FischerPU , WeilGJ . A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2013;7(11):e2447.">Krentel 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"To attempt to identify factors and patterns that are associated with compliance with MDA that apply across countries and cultures". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed‐methods: proportion of qualitative and quantitative studies unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013638-list-0003"> <li> <p>2000–2012</p> </li> <li> <p>Global</p> </li> <li> <p>"Studies that: (i) reviewed the literature on compliance with MDA for LF; (ii) described or assessed factors associated with compliance with MDA for LF; (iii) analysed, observed, or documented compliance rates with MDA and/or provided an explanation or discussion of the rates; and (iv) were identified from reference lists of primary papers". </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0074" title="AmesHM , ZuskeM , KingJD , SteinmannP , Bosch-CapblanchX . Community and drug distributor perceptions and experiences of mass drug administration for the elimination of lymphatic filariasis: a rapid review of qualitative research. Advances in Parasitology2019;103:117-49.">Ames 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"To rapidly review the existing qualitative literature to identify perspectives from the community and drug distributors. We focused on factors influencing feasibility of planning and carrying out campaigns and acceptability of MDA within community settings". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Qualitative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013638-list-0004"> <li> <p>2002–2017</p> </li> <li> <p>Global</p> </li> <li> <p>Qualitative studies and qualitative data that can be extracted from mixed‐methods studies </p> </li> <li> <p>Studies that "discussed community and/or drug distributor perceptions of and experiences with any form of MDA for LF elimination. Community encompasses people receiving treatment as well as those around them. A drug distributor can be anyone distributing medicines". </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>LF: lymphatic filariasis; MDA: mass drug administration.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of review studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/full#CD013638-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013638-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Programme design and delivery for included studies </span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Author</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rounds of MDA</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Programme organization</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Community engagement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Who delivers</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>How delivered</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adherence monitoring</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs and health staff</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0003" title="BabuBV , SatyanarayanaK . Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Tropical Doctor2003;33(2):79-82. ">Babu 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Yes<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0–1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0013" title="KingJD , Zielinski-GutierrezE , Pa'auM , LammieP . Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Tropica2011;120(Suppl 1):S48-54. ">King 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs and health staff</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door and "drug distribution booths set up at major work locations and the central market". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not mentioned </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door and "sometimes public places such as markets in urban areas".</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door ‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MDA‐naïve regions (Papua New Guinea, Indonesia) to 3 sites with multiple years of MDA rounds (India, Haiti, and Fiji)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"PHC network in rural areas and various categories of health staff in urban areas"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Door‐to‐door </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Distribution posts including: schools, markets, health facilities, churches, and local gathering places<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Village birth attendants, community based health workers,<br/>and teachers in drug distribution" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not mention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None mentioned</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CDD: community drug distributor; MDA: mass drug administration; PHC: primary Health Centre. </p> <p>For some studies, further information was provided by a: <a href="./references#CD013638-bbs2-0079" title="Biritwum NK, Frempong KK, Verver S, Odoom S, Alomatu B, Asiedu O,  et al. Progress towards lymphatic filariasis elimination in Ghana from 2000-2016: analysis of microfilaria prevalence data from 430 communities. PLoS Neglected Tropical Diseases2019;13(8):e0007115.">Biritwum 2019</a>; b: <a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a>; c: <a href="./references#CD013638-bbs2-0103" title="National Vector Bourne Disease Control Programme. Accelerated plan for elimination of lymphatic filariasis 2018. nvbdcp.gov.in/WriteReadData/l892s/1031567531528881007.pdf (accessed 19 January 2020).">NVBDCP 2018</a>; d: <a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a>; e: <a href="./references#CD013638-bbs2-0104" title="OscarR , LemoineJF , DirenyAN , DesirL , Beau de RocharsVE , PoirierMJ , et al. Haiti National Program for the elimination of lymphatic filariasis—a model of success in the face of adversity. PLoS Neglected Tropical Diseases2014;8(7):e2915.">Oscar 2014</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Programme design and delivery for included studies </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/full#CD013638-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013638-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Methodological limitations appraisal</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Author</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> <p><b>Were steps taken to increase rigour in the sampling?</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Were steps taken to increase rigour in the data collected?</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Were steps taken to increase rigour in the analysis of the data?</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Were the findings of the study grounded in/ supported by the data?</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Please rate the findings of the study in terms of their breadth and depth</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Overall, what weight would you assign to this study in terms of the reliability/trustworthiness of its findings?</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>What weight would you assign to this study in terms of the usefulness of its findings for this review?</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0001" title="AhorluCS , KokaE , Adu-AmankwahS , OtchereJ , deSouzaDK . Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. BMC Public Health2018;18(1):238. ">Ahorlu 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Medium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0002" title="AmarilloML , Belizario VY Jr, Sadiang-AbayJT , SisonSA , DayagAM . Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites &amp; Vectors2008;1(1):14. ">Amarillo 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0003" title="BabuBV , SatyanarayanaK . Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Tropical Doctor2003;33(2):79-82. ">Babu 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0004" title="BabuBV , NathN . The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Annals of Tropical Medicine and Parasitology2004;98(7):751-7. ">Babu 2004a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0005" title="BabuBV , KarSK . Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine &amp; International Health2004;9(6):702-9. ">Babu 2004b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0006" title="BabuBV , MishraS . Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Transactions of the Royal Society of Tropical Medicine and Hygiene2008;102(12):1207-13. ">Babu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0007" title="BabuBV . A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific Journal of Tropical Medicine2010;3(1):51-8. ">Babu 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0008" title="BanerjeeS , BandyopadhyayK , KhanMF , AkkilaguntaS , SelvarajK , TripathyJP , et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: a mixed method study. Journal of Family Medicine and Primary Care2019;8(9):3009-14. ">Banarjee 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0009" title="BiritwumNK , GarshongB , AlomatuB , deSouzaDK , GyapongM , KyelemD . Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana. PLoS Neglected Tropical Diseases2017;11(5):e0005619. ">Biritwum 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0010" title="CassidyT , WorrellCM , LittleK , PrakashA , PatraI , RoutJ , et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Neglected Tropical Diseases2016;10(2):e0004424. ">Cassidy 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0011" title="GonzalesM , BakerMC , CelestinoA , Santa MorilloD , ChamblissA , AdamsS , et al. How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. International Health2019;11(2):108-18. ">Gonzales 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth but limited depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0012" title="HussainMA , SithaAK , SwainS , KadamS , PatiS . Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty2014;3:31. ">Hussain 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0013" title="KingJD , Zielinski-GutierrezE , Pa'auM , LammieP . Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Tropica2011;120(Suppl 1):S48-54. ">King 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/ can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0014" title="KisokaWJ , TersbolBP , MeyrowitschDW , SimonsenPE , MushiDL . Community members perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania. Journal of Biosocial Science2016;48(1):94-112. ">Kisoka 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good depth and breadth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0015" title="KisokaW , MushiD , MeyrowitschDW , MalecelaM , SimonsenPE , TersbolBP . Dilemmas of community-directed mass drug administration for lymphatic filariasis: a qualitative study from urban and rural Tanzania. Journal of Biosocial Science2017;49(4):447-62. ">Kisoka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0016" title="KrentelA , AungerR . Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy and Planning2012;27(5):384-95. KrentelA , WellingsK . The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. Parasites &amp; Vectors2018;11(1):179. KrentelA . Why do individuals comply with mass drug administration for lymphatic filariasis? A case study from Alor District, Indonesia [PhD thesis]. Available at: researchonline.lshtm.ac.uk/1742274/. London (UK): London School of Hygiene and Tropical Medicine, 2008. ">Krentel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0017" title="KrentelA , BaskerN , Beau de RocharsM , BogusJ , DilliottD , DirenyAN , et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases2021;15(3):e0009002. ">Krentel 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0018" title="Kusi C, SteinmannP , MertenS . The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Infectious Diseases of Poverty2020;9(1):22. ">Kusi 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth but limited depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0019" title="ManyehAK , IbisomiL , RamaswamyR , BaidenF , ChirwaT . Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana. PLoS Neglected Tropical Diseases2020;14(8):e0007009. ">Manyeh 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Medium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0020" title="ManyehAK , ChirwaT , RamaswamyR , BaidenF , IbisomiL . Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework. Tropical Medicine and Health2021;49(1):16. ">Manyeh 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0021" title="NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. Southern African Journal of Epidemiology &amp; Infection2012;27(2):66-70. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NgurePK , NjengaSM . Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. African Journal of Health Sciences2012;20(1):42-9. NjomoDW , Amuyunzu-NyamongoM , MagamboJK , NjengaSM . The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One2012;7(11):e48395. ">Njomo 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0022" title="NjomoDW , MukokoDA , NyamongoNK , KaranjaJ . Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. PLoS One2014;9(1):e83413. ">Njomo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth but limited depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0023" title="NjomoDW ,  KibeILW ,  KimaniBW , OkoyoC ,  OmondiWP , SultaniIHM . Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLoS Neglected Tropical Diseases2020;14(9):e0008499. ">Njomo 2020a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth but limited depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0024" title="NjomoDW , KimaniBW , KibeLW , OkoyoC , OmondiWP , SultaniHM . Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: perceptions and experiences of community drug distributors of coastal Kenya. PLoS One2020;14(12):e0009012. ">Njomo 2020b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0025" title="ParkerM , AllenT . Will mass drug administration eliminate lymphatic filariasis? Evidence from northern coastal Tanzania. Journal of Biosocial Science2013;45(4):517-45. ">Parker 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Medium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0026" title="RamaiahKD , DasPK , AppavooNC , RamuK , AugustinDJ , KumarKN , et al. A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Tropical Medicine &amp; International Health2000;5(12):842-7. ">Ramaiah 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0027" title="SilumbweA , HalwindiH , ZuluJM . How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: the case of Luangwa District, Zambia. PLoS Neglected Tropical Diseases2019;13(11):e0007861. ">Silumbwe 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/ can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth but limited depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0028" title="WodnikBK , LouisDH , JosephM , WilkersLT , LandskroenerSD , DesirL , et al. The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: a case study. PLoS Neglected Tropical Diseases2020;14(5):e0008318. ">Wodnik 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a few steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth and depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013638-bbs2-0029" title="WyndS , CarronJ , SelveB , LeggatPA , MelroseW , DurrheimDN . Qualitative analysis of the impact of a lymphatic filariasis elimination programme using mass drug administration on Misima Island, Papua New Guinea. Filaria Journal2007;6:1. ">Wynd 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, several steps were taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, a fairly thorough attempt was made</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated/can't tell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fair grounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good breadth but limited depth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium<br/>  </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Methodological limitations appraisal</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013638.pub2/full#CD013638-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013638.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013638-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013638-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013638-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD013638-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD013638-note-0008">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013638-note-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013638-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013638\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013638\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013638\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013638\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013638\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013638\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013638\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013638\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013638\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013638\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013638\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013638\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013638\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013638\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013638\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013638\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013638\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013638\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UiM8QuvV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013638.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013638.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013638.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013638.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013638.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718898667"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013638.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718898670"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013638.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ddb91bb951be5',t:'MTc0MDcxODg5OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 